

## CURRICULUM VITAE

**Personal Information**

---

Name: Joan Seoane  
 Address: Vall d'Hebron Institute of Oncology (VHIO)  
 Vall d'Hebron University Hospital  
 c/ Natzaret 115-117  
 08035 - Barcelona, Spain  
 Phone: +34 93 254 34 50 ext. 8641  
 E-mail: [jseoane@vhio.net](mailto:jseoane@vhio.net)

**Education**

---

*1989-1993: B.Sc. Chemistry, University of Barcelona, Barcelona, Spain.*

*Jul-Sep 1991: Student researcher, Boehringer Ingelheim, Malgrat, Spain. Director of the project: C. von Carsten, Ph.D.*

*Jul-Nov 1993: Student researcher, Boehringer Ingelheim, Ingelheim, Germany. Director of the project: C. Naumann, Ph.D.*

*1994-1998: Ph.D. Student in Chemistry, Dept. Biochemistry and Molecular Biology, University of Barcelona (UB), Barcelona, Spain.*

*Jul-Sep 1997: Short stay at laboratory of C.B. Newgard, Ph.D., Professor, Dept. of Biochemistry and Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX.*

*17<sup>th</sup> Apr 1998: Ph.D. in Chemistry, Program of Biochemistry, University of Barcelona (UB), Dept. Biochemistry and Molecular Biology. Barcelona, Spain.*

*1<sup>st</sup> May - 5<sup>th</sup> Jun 1998: Short stay at laboratory of Lorraine Agius, Ph.D., Reader in Biochemistry, University of Newcastle upon Tyne, Dept. of Medicine, Newcastle, UK.*

*15<sup>th</sup> Jul 1998-15<sup>th</sup> Jul 2001: Research Fellow, Memorial Sloan-Kettering Cancer Center, New York.*

*15<sup>th</sup> Jul 2001- Dec 2003: Research Associate, Memorial Sloan-Kettering Cancer Center, New York.*

*Jan 2004-present: ICREA Research Professor, Group Leader, Medical Oncology Program, Vall d'Hebron University Hospital, Barcelona, Spain.*

*Sep 2006-present: Member of the Neuro-Oncology Committee. Vall d'Hebron Hospital, Barcelona, Spain.*

*Oct 2007: EMBO (European Molecular Biology Organization) Young Investigator.*

*Apr 2008-present: Group Leader, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital, Barcelona, Spain.*

*Sep 2008-present: Associate Professor, Universitat Autònoma de Barcelona (UAB), Barcelona, Spain.*

*Sep 2008-2012: Associate Coordinator Spanish National Agency of Grant Evaluation (ANEP).*

*Oct 2008-present: Board Member of the European Association for Cancer Research (EACR).*

*Jan 2010-present: Member of the Executive Committee, VHIO, Barcelona, Spain.*

*Jun 2011-present: Director, Translational Research Program, VHIO, Barcelona, Spain.*

*May 2012: Founder and Chairman of Mosaic Biomedicals S.L.U. A VHIO and ICREA Spin-off Biotech Company.*

*Jan 2015-2019: Associate Coordinator Instituto de Salud Carlos III (FIS) Grant Evaluation panel.*

*Jan 2015-present: Faculty member of the European Society for Medical Oncology (ESMO).*

*Jul 2016-present: Secretary General of the European Association for Cancer Research (EACR).*

*Oct 2017: Fellow of the European Academy of Cancer Sciences (EACS).*

*Dec 2017-present: Board Member of the Asociación Española contra el Cáncer (AECC).*

*Feb 2019-2022: Member of the Bosarge Family Foundation-Waun Ki Hong Scholar Award for Regenerative Cancer Medicine Scientific Review Committee (from the AACR)*

*May 2019- present: co-Director, Preclinical and Translational Research Program, VHIO, Barcelona, Spain.*

## Awards

---

Grantor: Pfizer Foundation

**Scientific Innovation Award for Young Researchers**

**To Laura Escudero for our article Escudero et al. 2020 | November 2021**

Grantor: La Vanguardia & Fundació Catalunya La Pedrera

**Premio Vanguardia de la Ciencia | April 2016**

Grantor: Fundación para la Investigación del Cáncer de la Universidad de Salamanca (FICUS) y Centro de Investigación del Cáncer (CIC)

**IV Premio Nacional Doctores Diz Pintado | January 2015**

Grantor: The Dr. Josef Steiner Cancer Research Foundation

**Dr. Josef Steiner Cancer Research Award 2013 | April 2013**

Grantor: Sociedad Española de Bioquímica y Biología Molecular

**Beckman-Coulter Award | September 2009**

Grantor: Banco Sabadell

**Biomedical Research Award | July 2009**

Grantor: European Molecular Biology Organization (EMBO)

**EMBO Young Investigator | October 2007**

Grantor: Societat Catalana de Biologia

**Josep M. Sala Trepat Award | July 2004**

Grantor: Memorial Sloan-Kettering Cancer Center

**MSKCC Research Fellow Award | April 2003**

## Publication List

---

- Hallett R, Bonfill-Teixidor E, Iurlaro R, Arias A, Raman S, Bayliss PE, Egorova O, Neva-Alejo A, McGray AR, Lau E, Bosch A, Beilschmidt M, Maetzel D, Fransson J, Huber-Ruano I, Anido J, Julien JP, Giblin PA, **Seoane J** Therapeutic targeting of LIF overcomes macrophage mediated immunosuppression of the local tumor microenvironment. *Clin Cancer Res.* 2022; Online ahead of print.
- Iurlaro R, Inja Waldhauer, Ester Planas-Rigol , Ester Bonfill-Teixidor, Alexandra Arias, Valeria Nicolini, Anne Freimoser-Grundschober, Isabel Cuartas, Alba Martínez-Moreno, Francisco Martínez-Ricarte , Esteban Cordero, Marta Cicuendez, Simona Casalino, Xavier Guardia-Reyes, Linda Fahrni , Thomas Pöschinger , Virginie Steinhart, Marine Richard, Stefanie Briner, Joerg Mueller, Franz Osl, Johannes Sam, Sara Colombetti, Marina Bacac, Christian Klein, Estela Pineda, Luis Reyes-Figueroa, Alberto Di Somma, Josep González, Paolo Nuciforo, Joan Carles, Maria Vieito, Josep Tabernero, Pablo Umaña , **Seoane, J.** A Novel EGFRvIII T-Cell Bispecific Antibody for the Treatment of Glioblastoma. *Mol Cancer Ther.* 2022;21(10):1499-1509.
- J. Pascual, G. Attard, F.-C. Bidard, G. Curigliano, L. De Mattos-Arruda, M. Diehn, A. Italiano J. Lindberg, J.D. Merker C. Montagut, N. Normanno, K. Pantel, G. Pentheroudakis, S. Papat, J.S. Reis-Filho, J. Tie , **Seoane, J.**, N. Tarazona, T. Yoshino, N.C. ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group. *Annals of Oncology*, 2022; 33(8):750-768.
- E. Borazanci , A. M. Schram, E. Garralda, I. Brana , M. Vieito Villar , A. Spreafico , M. Oliva, N. J. Lakhani , K. Hoffman, R. M. Hallett , D. Maetzel , F. Hua , J. Hilbert , P. Giblin , J. Anido , A. Kelly , P. J. Vickers , R. Wasserman, **Seoane, J** , L. L. Siu , D. M. Hyman , D. V. Hoff & J. Tabernero. Phase I, first-in-human study of MSC-1 (AZD0171), a humanized anti-leukemia inhibitory factor monoclonal antibody, for advanced solid tumors. *Clinical Trial. ESMO Open.* 2022, 7(4):100530.
- Bonfill-Teixidor E, Iurlaro R, Handl C, Wichmann J, Arias A, Cuartas I, Emmenegger J, Romagnani A, Mangano L, Lorber T, Berrera M, Godfried Sie C, Köchl F, Eckmann J, Feddersen R, Kornacker M, Schnetzler G, Cicuéndez M, Cordero E, Topczewski TE, Ferrés-Pijoan A, Gonzalez J, Martínez-Ricarte F, Muñoz-Couselo E, Tabernero J, Bischoff JR, Pettazoni P, **Seoane J.** Activity and resistance of a brain-permeable paradox breaker BRAF inhibitor in melanoma brain metastasis. *Cancer Res.* 2022, 18;82(14):2552-2564.
- Soffiatti R, Bettegowda C, Mellinghoff IK, Warren KE, Ahluwalia MS, De Groot JF, Galanis E, Gilbert MR, Jaeckle KA, Le Rhun E, Rudà R, **Seoane J**, Thon N, Umemura Y, Weller M, van den Bent MJ, Vogelbaum MA, Chang SM, Wen PY. Liquid biopsy in gliomas: a RANO review and proposals for clinical applications. *Neuro Oncology.* 2022, 1;24(6):855-871
- Seoane J**, Escudero L. Cerebrospinal fluid liquid biopsies for medulloblastoma. *Nature Reviews Clinical Oncology.* 2022;19(2):73-74.
- Gulley JL, Schlom J, Barcellos-Hoff MH, Wang XJ, **Seoane J**, Audhuy F, Lan Y, Dussault I, Moustakas A. Dual inhibition of TGF- $\beta$  and PD-L1 as a novel cancer treatment approach. *Molecular Oncology.* 2022;16(11):2117-2134.
- Nieto P, Elosua-Bayes M, Trincado JL, Marchese D, Massoni-Badosa R, Salvany M, Henriques A, Nieto J, Aguilar-Fernández S, Mereu E, Moutinho C, Ruiz S, Lorden P, Chin VT, Kaczorowski D, Chan CL, Gallagher R, Chou A, Planas-Rigol E, Rubio-Perez C, Gut I, Piulats JM, **Seoane J**, Powell JE, Batlle E, Heyn H. A single-cell tumor immune atlas for precision oncology. *Genome Res.* 2021; (10):1913-1926.
- Le Rhun E, Guckenberger M, Smits M, Dummer R, Bachelot T, Sahm F, Galldiks N, de Azambuja E, Berghoff AS, Metellus P, Peters S, Hong Y-K, Winkler F, Schadendorf D, van den Bent M, **Seoane J**, Stahel R, Minniti G, Wesseling P, Weller M & Preusser M on behalf of the EANO Executive Board and ESMO Guidelines Committee\*. EANO–ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumors. *Annals of Oncology.* 2021; 32(11): 1332-1347.

- Ligero Hernández M, Garcia Ruiz A, Viaplana C, Villacampa Javierre G, Raciti MV, Landa J, Matos I, Martin Liberal JJ, Ochoa de Olza M, Hierro C, Mateo J, Gonzalez Rodriguez M, Morales R, Suárez C, Rodon J, Élez E, Braña I, Muñoz Couselo E, Oaknin A, Fasani R, Nuciforo P, Gil D, Rubio-Pérez C, **Seoane J**, Felip E, Escobar M, Tabernero J, Carles J, Dienstmann R, Garralda E, Perez Lopez R. A CT-based Radiomics Signature Is Associated with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors. *Radiology*. 2021 ;299(1):109-119.
- Escudero L , Martínez-Ricarte F, **Seoane J**. ctDNA-Based Liquid Biopsy of Cerebrospinal Fluid in Brain Cancer. *Cancers (Basel)*. 2021;13(9):1989.
- Cribiù FM, Erra R, Pagni L, Rubio Perez C, Alonso L, Simonetti S, Croci GA, Serna G, Ronchi A, Pietrasanta C, Lunghi G, Fagnani AM, Pinana M, Matter M, Tzankov A, Terracciano L, Anton Pagarolas A, Ferrazzi E, Ferrero S, Iurlaro E, **Seoane J\***, Nuciforo P\*. Severe SARS-CoV-2 placenta infection can impact neonatal outcome in the absence of vertical transmission. (\*co-corresponding authors). *Journal of Clinical Investigation*. 2021;131(6):e145427.
- Rubio-Perez C, Planas-Rigol E, Trincado JL, Bonfill-Teixidor E, Arias A, Marchese D, Moutinho C, Serna G, Pedrosa L, Iurlaro R, Martínez-Ricarte F, Escudero L, Cordero E, Cicuendez M, Ruiz S, Parra G, Nuciforo P, Gonzalez J, Pineda E, Sahuquillo J, Tabernero J, Heyn H, **Seoane J**. Immune cell profiling of the cerebrospinal fluid enables the characterization of the brain metastasis microenvironment. *Nature Communications*. 2021;12(1):1503.
- Puyol M, **Seoane J**, Aguilar E, Vozza LB, Orbe I, Crawford KH, Fernández A, Bray F, Johnson SE, Gopal S. WORLD CANCER RESEARCH DAY: A call to action for a coordinated international research effort to prevent, diagnose and treat cancer. *Clinical Cancer Research*. 2021;27(4):963-966.
- Bobillo S, Crespo M, Escudero L, Mayor R, Raheja P, Carpio C, Rubio-Perez C, Tazón-Vega B, Palacio C, Carabia J, Jiménez I, Nieto JC, Montoro J, Martínez-Ricarte F, Castellví J, Simó M, Puigdefàbregas L, Abrisqueta P, Bosch F, **Seoane J**. Cell free circulating tumor DNA in cerebrospinal fluid detects and monitors central nervous system involvement of B-cell lymphomas. *Haematologica*. 2021;106(2):513-521.
- Galson JD, Schaetzle S, Bashford-Rogers RJM, Raybould MIJ, Kovaltsuk A, Kilpatrick GJ, Minter R, Finch DK, Dias J, James LK, Thomas G, Jason Lee WY, Betley J, Cavlan O, Leech A, Deane CM, **Seoane J**, Caldas C, Pennington DJ, Pfeffer PE, Osbourn J. Deep sequencing of B cell receptor repertoires from COVID-19 patients reveals strong convergent immune signatures. *Frontiers in Immunology*. 2020;11:605170.
- Escudero L, Martínez-Ricarte F, **Seoane J**. Cerebrospinal fluid circulating tumour DNA as a liquid biopsy for central nervous system malignancies. *Current Opinion Neurology*. 2020; 33(6):736-741.
- Ciardello D, Elez ME, Tabernero J, **Seoane J**. Clinical development of therapies targeting TGFβ: current knowledge and future perspectives. *Annals of Oncology*. 2020;31(10):1336-1349.
- Escudero L, Llorca A, Arias A, Diaz-Navarro A, Martínez-Ricarte F, Rubio-Perez C, Mayor R, Caratú G, Martínez-Sáez E, Vázquez-Méndez É, Lesende-Rodríguez I, Hladun R, Gros L, Ramón y Cajal S, Poca M, Puente X, Sahuquillo J, Gallego S, **Seoane J**. Circulating tumour DNA from the cerebrospinal fluid allows the characterisation and monitoring of medulloblastoma. *Nature Communications*. 2020;11(1):5376.
- Jiménez, I, Carabia J, Bobillo S, Palacio C, Abrisqueta P, Pagès C, Nieto JC, Castellví J, Martínez-Ricarte F, Escoda L, Perla C, Céspedes-Torrez DH, Boix J, Purroy N, Puigdefàbregas L, **Seoane J**, Bosch F, Crespo M. Repolarization of tumor infiltrating macrophages and increased survival in mouse primary CNS lymphomas after XPO1 and BTK inhibition. *Journal of Neuro-Oncology*. 2020;149(1):13-25.

- Le Rhun E, **Seoane J**, Salzet M, Soffiotti R, Weller M. Liquid biopsies for diagnosing and monitoring primary tumors of the central nervous system. *Cancer letters*. 2020; 480:24-28.
- Seoane J**. Immunotherapy Research: today's science is tomorrow's medicine. *The Innovation Platform*. 2020; 1: 122-123.
- Gargini R, Segura-Collar B, Herránz B, Garcia-Escudero V, Romero-Bravo A, Núñez FJ, García-Pérez D, Gutiérrez-Guamán J, Ayuso-Sacido A, **Seoane J**, Pérez-Núñez A, Sepúlveda-Sánchez JM, Hernández-Laín A, Castro MG, García-Escudero R, Ávila J, Sánchez-Gómez P. The IDH-TAU-EGFR triad defines the neovascular landscape of diffuse gliomas. *Science Translational Medicine*. 2020;12(527):eaax1501.
- Janin M, Ortiz-Barahona V, de Moura MC, Martínez-Cardús A, Llinàs-Arias P, Soler M, Nachmani D, Pelletier J, Schumann U, Calleja-Cervantes ME, Moran S, Guil S, Bueno-Costa A, Piñeyro D, Perez-Salvia M, Rosselló-Tortella M, Piqué L, Bech-Serra JJ, De La Torre C, Vidal A, Martínez-Iniesta M, Martín-Tejera JF, Villanueva A, Arias A, Cuartas I, Aransay AM, La Madrid AM, Carcaboso AM, Santa-Maria V, Mora J, Fernandez AF, Fraga MF, Aldecoa I, Pedrosa L, Graus F, Vidal N, Martínez-Soler F, Tortosa A, Carrato C, Balañá C, Boudreau MW, Hergenrother PJ, Kötter P, Entian KD, Hench J, Frank S, Mansouri S, Zadeh G, Dans PD, Orozco M, Thomas G, Blanco S, **Seoane J**, Preiss T, Pandolfi PP, Esteller M. Epigenetic loss of RNA-methyltransferase NSUN5 in glioma targets ribosomes to drive a stress adaptive translational program. *Acta Neuropathologica*. 2019;138(6):1053-1074.
- Siravegna G, Mussolin B, Venesio T, Marsoni S, **Seoane J**, Dive C, Papadopoulos N, Kopetz S, Corcoran R. B, Siu L. L, and Bardelli A. How liquid biopsies can change clinical practice in oncology. *Annals of Oncology*. 2019;30(10):1580-1590.
- Seoane J**. Beyond blood with liquid biopsies. *ESMO Perspectives*. 2019.
- Pascual-García M, Bonfill-Teixidor E, Planas-Rigol E, Rubio-Pérez C, Iurlaro R, Arias A, Cuartas I, Sala-Hojman A, Escudero E, Martínez-Ricarte F, Huber-Ruano I, Nuciforo P, Pedrosa L, Marques C, Braña I, Garralda E, Vieito M, Squatrito M, Pineda E, Graus F, Espejo C, Sahuquillo J, Tabernero J, **Seoane J**. LIF regulates CXCL9 in tumor-associated macrophages and prevents CD8+ T cell tumor-infiltration impairing the response to anti-PD1 therapy. *Nature Communications*. 2019;10(1):2416.
- De Mattos-Arruda L, Sammut SJ, Ross EM, Bashford-Rogers R, Greenstein E, Markus H, Morganello S, Teng Y, Maruvka Y, Pereira B, Rueda OM, Chin SF, Contente-Cuomo T, Mayor R, Arias A, Ali HR, Cope W, Tiezzi D, Dariush A, Dias Amarante T, Reshef D, Ciriaco N, Martinez-Saez E, Peg V, Ramon Y Cajal S, Cortes J, Vassiliou G, Getz G, Nik-Zainal S, Murtaza M, Friedman N, Markowitz F, **Seoane J\***, Caldas C\*. The Genomic and Immune Landscapes of Lethal Metastatic Breast Cancer. (\*co-corresponding authors). *Cell Reports*. 2019;27(9):2690-2708.e10.
- Seoane J**, De Mattos-Arruda L, Le Rhun E, Bardelli A, Weller M. Cerebrospinal fluid cell-free tumour DNA as a liquid biopsy for primary brain tumours and brain metastases. *Annals of Oncology*. 2019;30(2):211-218.
- Liu Q, Ma L, Jones T, Palomero L, Pujana MA, Martinez-Ruiz H, Ha P, Murnane J, Cuartas I, **Seoane J**, Baumann M, Linge A, Barcellos-Hoff MH. Subjugation of Tgfβ signaling by human papilloma virus in head and neck squamous cell carcinoma shifts DNA repair from homologous recombination to alternative end joining. *Clinical Cancer Research*. 2018;24(23):6001-6014.
- Rius Ruiz I, Vicario R, Morancho B, Morales CB, Arenas EJ, Herter S, Freimoser-Grundschober A, Somandin J, Sam J, Ast O, Barriocanal ÁM, Luque A, Escorihuela M, Varela I, Cuartas I, Nuciforo P, Fasani R, Peg V, Rubio I, Cortés J, Serra V, Escriba-de-Romani S, Sperinde J, Chenna A, Huang W, Winslow J, Albanell J, **Seoane J**, Scaltriti M, Baselga J, Tabernero J, Umana P, Bacac M, Saura C, Klein C, Arribas J. p95HER2-T cell bispecific antibody for breast cancer treatment. *Science Translational Medicine*. 2018;10(461): eaat1445.

- Puig I, Tenbaum SP, Chicote I, Arques O, Martínez-Quintanilla J, Cuesta-Borrás E, Ramírez L, Gonzalo P, Soto A, Aguilar S, Eguizabal C, Caratu G, Prat A, Argilés G, Landolfi S, Casanovas O, Serra V, Villanueva A, Arroyo A, Terracciano L, Nuciforo P, **Seoane J**, Recio JA, Vivancos A, Dienstmann R, Tabernero J, Palmer HG. TET2 Controls Chemoresistant Slow-Cycling Cancer Cells Survival and Tumour Recurrence. *Journal of Clinical Investigation*. 2018;128(9):3887-3905.
- Seoane J**, Capdevila J. The right compound for the right target: tackling RET. *Annals of Oncology*. 2018;29(8):1623-1625.
- Martínez-Ricarte F., Mayor R., Martínez-Sáez E., Rubio-Pérez C., Pineda E., Cordero E., Cicuéndez M., Poca MA., López-Bigas N., Ramon y Cajal S., Vieito M., Carles J., Tabernero J., Vivancos A., Gallego S., Graus F., Sahuquillo J., **Seoane J**. Molecular diagnosis of diffuse gliomas through sequencing of cell-free circulating tumour DNA from cerebrospinal fluid. *Clinical Cancer Research*. 2018;24(12):2812-2819.
- Capdevila J, Mayor R, Mancuso FF, Iglesias C, Caratù G, Matos I, Zafón C, Hernando J, Petit A, Nuciforo P, Cameselle-Teijeiro JM, Álvarez C, Recio JA, Tabernero J, Matias-Guiu X, Vivancos A, **Seoane J**. Early evolutionary divergence between papillary and anaplastic thyroid cancers. *Annals of Oncology*. 2018;29(6):1454-1460.
- De Mattos-Arruda L, Ng CKY, Piscuoglio S, Gonzalez-Cao M, Lim RS, De Filippo MR, Fusco N, Schultheis AM, Ortiz C, Viteri S, Arias A, Macedo GS, Oliveira M, Gomez P, Teixidó C, Nuciforo P, Peg V, Saura C, Ramon Y Cajal S, Casas FT, Weigelt B, Cortes J, **Seoane J**, Reis-Filho JS. Genetic heterogeneity and actionable mutations in HER2-positive primary breast cancers and their brain metastases. *Oncotarget*. 2018;9(29):20617-20630.
- Yates L. R., **Seoane J**, Le Tourneau C., Siu L.L., Marais R., Michiels S., Soria J.C., Campbell P., Normanno N., Scarpa A., Reis-Filho J., Rodon J., Swanton C., Andre F. The European Society of Medical Oncology (ESMO) Precision Medicine Glossary. *Annals of Oncology*. 2018;29(1):30-35.
- Seoane J**, Gomis RR. TGF $\beta$  Family Signaling in Tumor Suppression and Cancer Progression. *Cold Spring Harbor Perspectives in Biology*. 2017;9(12):a022277.
- Seoane J**. Cancer Division hierarchy leads to cell heterogeneity. *Nature*. 2017;549(7671):164-166.
- Huber-Ruano I, Raventos C, Cuartas I, Sánchez-Jaro C, Wosikowski K, Janicot M, **Seoane J**. An antisense oligonucleotide targeting TGF- $\beta$ 2 inhibits lung metastasis and induces CD86 expression in tumor-associated macrophages. *Annals of Oncology*. 2017;28(9):2278-2285.
- Gonzalez-Cao M, Berrocal A, Puig S, Karachaliou N, De Matos-Arruda L, **Seoane J**, Escors D, Alvarez C, Vaque J P, Prat A, Wellbrock C, Arozarena I, Marquez-Rodas I, Espinosa E, Molina M A, Puertolas T, Juan-Otero M, Malagrida R, Jantus-Lewintre E, Soriano V, Arance A, Manzano J L, Lorigan P, Gajewski T F, Rosell R, Martin-Algarra S; On behalf of the Spanish Melanoma Group (GEM) Report from the II Melanoma Translational Meeting of the Spanish Melanoma Group (GEM). *Annals of Translational Medicine* 2017; 5(19):390.

- Byrne AT, Alférez DG, Amant F, Annibali D, Arribas J, Biankin AV, Bruna A, Budinská E, Caldas C, Chang DK, Clarke RB, Clevers H, Coukos G, Dangles-Marie V, Eckhardt SG, Gonzalez-Suarez E, Hermans E, Hidalgo M, Jarzabek MA, de Jong S, Jonkers J, Kemper K, Lanfrancone L, Mælandsmo GM, Marangoni E, Marine JC, Medico E, Norum JH, Palmer HG, Peeper DS, Pelicci PG, Piris-Gimenez A, Roman-Roman S, Rueda OM, **Seoane J**, Serra V, Soucek L, Vanhecke D, Villanueva A, Vinolo E, Bertotti A, Trusolino L. Interrogating open issues in cancer precision medicine with patient-derived xenografts. *Nature Reviews Cancer*. 2017;17(4):254-268.
- Gueorguieva I, Cleverly A, Desai D, Azaro A, **Seoane J**, Braña I, Sicart E, Miles C, Lahn MM, Mitchell MI, Rodon J. Relative bioavailability of three formulations of galunisertib administered as monotherapy in patients with advanced or metastatic cancer. *Drugs in Context*. 2016;5:212303.
- Seoane J**. The Taming of the TAMs. *Trends in Cell Biology*. 2016;26(8):562-3.
- De Mattos-Arruda L, Mayor R, Ng CKY, Weigelt B, Martínez-Ricarte F, Torrejon D, Oliveira M, Arias A, Raventos C, Tang J, Guerini-Rocco E, Martínez-Sáez E, Lois S, Marín O, de la Cruz X, Piscuoglio S, Towers R, Vivancos A, Peg V, Ramon y Cajal S, Carles J, Rodon J, González-Cao M, Tabernero J, Felip E, Sahuquillo J, Berger MF, Cortes J, Reis-Filho JS, **Seoane J**. Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma. *Nature Communications*. 2015;6:8839.
- De Mattos-Arruda L, Bottai G, Nuciforo PG, Di Tommaso L, Giovannetti E, Peg V, Losurdo A, Pérez-García J, Masci G, Corsi F, Cortés J, **Seoane J**, Calin GA, Santarpia L. MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients. *Oncotarget*. 2015;6(35):37269-80.
- Brastianos PK, Carter SL, Santagata S, Cahill DP, Taylor-Weiner A, Jones RT, Van Allen EM, Lawrence MS, Horowitz PM, Cibulskis K, Ligon KL, Tabernero J, **Seoane J**, Martinez-Saez E, Curry WT, Dunn IF, Paek SH, Park SH, McKenna A, Chevalier A, Rosenberg M, Barker FG 2nd, Gill CM, Van Hummelen P, Thorner AR, Johnson BE, Hoang MP, Choueiri TK, Signoretti S, Sougnez C, Rabin MS, Lin NU, Winer EP, Stemmer-Rachamimov A, Meyerson M, Garraway L, Gabriel S, Lander ES, Beroukhi R, Batchelor TT, Baselga J, Louis DN, Getz G, Hahn WC. Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets. *Cancer Discovery*. 2015;5(11):1164-1177.
- Iyengar PV, Jaynes P, Rodon L, Lama D, Law KP, Lim YP, Verma C, **Seoane J**, Eichhorn PJ. USP15 regulates SMURF2 kinetics through C-lobe mediated deubiquitination. *Scientific Reports*. 2015; 5:14733.
- Rodon J, Carducci M, Sepulveda-Sánchez JM, Azaro A, Calvo E, **Seoane J**, Braña I, Sicart E, Gueorguieva I, Cleverly A, Pillay NS, Desai D, Estrem ST, Paz-Ares L, Holdhoff M, Blakeley J, Lahn MM, Baselga J. Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor- $\beta$  receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer. *Investigational New Drugs*. 2015;33(2):357-70.
- Ulloa F, González-Juncà A, Meffre D, Barrecheguren PJ, Martínez-Mármol R, Pazos I, Olivé N, Cotrufo T, **Seoane J**, Soriano E. Blockade of the SNARE Protein Syntaxin 1 Inhibits Glioblastoma Tumor Growth. *PLoS One*. 2015;10(3):e0119707.

- Rodon J, Carducci MA, Sepulveda-Sanchez JM, Azaro A, Calvo E, **Seoane J**, Brana I, Sicart E, Gueorguieva I, Cleverly AL, Sokalingum Pillay N, Desai D, Estrem ST, Paz-Ares L, Holdoff M, Blakeley J, Lahn MM, Baselga J. First-in-Human Dose Study of the Novel Transforming Growth Factor- $\beta$  Receptor I Kinase Inhibitor LY2157299 Monohydrate in Patients with Advanced Cancer and Glioma. *Clinical Cancer Research*. 2015;21(3):553-60.
- Seoane J**, De Mattos-Arruda L. Escaping out of the brain. *Cancer Discovery*. 2014;4(11):1259-61.
- Rodon L, Gonzalez-Junca A, Inda MD, Sala-Hojman A, Martinez-Saez E, **Seoane J**. Active CREB1 promotes a malignant TGF- $\beta$ 2 autocrine loop in glioblastoma. *Cancer Discovery*. 2014;4(10):1230-41.
- Henderson D, Ogilvie LA, Hoyle N, Keilholz U, Lange B, Lehrach H on behalf of the OncoTrack Consortium. Personalized medicine approaches for colon cancer driven by genomics and systems biology: *OncoTrack. Biotechnology Journal*. 2014;9(9):1104-14.
- Hidalgo M, Amant F, Biankin AV, Budinská E, Byrne AT, Caldas C, Clarke RB, de Jong S, Jonkers J, Mælandsmo GM, Roman-Roman S, **Seoane J**, Trusolino L, Villanueva A. Patient-Derived Xenograft Models: An Emerging Platform for Translational Cancer Research. *Cancer Discovery*. 2014;4(9):998-1013.
- Annibali D, Whitfield JR, Favuzzi E, Jauset T, Serrano E, Cuartas I, Redondo-Campos S, Folch G, Gonzalez-Juncà A, Sodir NM, Masso-Vallés D, Beaulieu ME, Swigart LB, Mc Gee MM, Somma MP, Nasi S, **Seoane J**, Evan GI, Soucek L. Myc inhibition is effective against glioma and reveals a role for Myc in mitosis. *Nature Communications*. 2014; 5:4632.
- De Mattos-Arruda L, Weigelt B, Cortes J, Won HH, Ng CK, Nuciforo P, Bidard FC, Aura C, Saura C, Peg V, Piscuoglio S, Oliveira M, Smolders Y, Patel P, Norton L, Taberero J, Berger MF, **Seoane J**, Reis-Filho JS. Capturing Intra-Tumor Genetic Heterogeneity by De Novo Mutation Profiling of Circulating Cell-Free Tumor DNA: A Proof-of-Principle. *Annals of Oncology*. 2014;25(9):1729-1735.
- Seoane J**, De Mattos-Arruda L. Brain metastasis: new opportunities to tackle therapeutic resistance. Review Article, *Molecular Oncology*. 2014;8(6):1120-31.
- Seoane J**, De Mattos-Arruda L. The challenge of intratumour heterogeneity in precision medicine. *Journal of Internal Medicine*. 2014;276(1):41-51.
- Martino-Echarri E, Fernández-Rodríguez R, Bech-Serra JJ, Plaza-Calonge MC, Vidal N, Casal C, Colomé N, **Seoane J**, Canals F, Rodríguez-Manzaneque JC. Relevance of IGFBP2 proteolysis in glioma and contribution of the extracellular protease ADAMTS1. *Oncotarget*. 2014;5(12):4295-304.
- Seoane J**. Gremlins Sabotage the Mechanisms of Cancer Stem Cell Differentiation. *Cancer Cell*. 2014;25(6):716-7.
- De Mattos-Arruda L, Bidard FC, Won HH, Cortes J, Ng CK, Peg V, Nuciforo P, Jungbluth AA, Weigelt B, Berger MF, **Seoane J\***, Reis-Filho JS\*. Establishing the origin of metastatic deposits in the setting of multiple primary malignancies: The role of massively parallel sequencing. *Molecular Oncology*. 2014;8(1):150-8. (\*co-corresponding authors).
- Cortés J, Calvo E, Vivancos A, Perez-Garcia J, Recio JA, **Seoane J**. New approach to cancer therapy based on a molecularly defined cancer classification. *CA: A Cancer Journal for Clinicians*. 2014;64(1):70-4.
- Inda MD, Bonavia R, **Seoane J**. Glioblastoma multiforme: a look inside its heterogeneous nature. *Cancers (Basel)*. 2014;6(1):226-39.



- Serra V, Vivancos A, Puente XS, Felip E, Silberschmidt D, Caratu G, Parra JL, De Mattos-Arruda L, Grueso J, Hernandez-Losa J, Arribas J, Prudkin L, Nuciforo P, Scaltriti M, **Seoane J\***, Baselga J\*. Clinical response to a lapatinib-based therapy of a Li-Fraumeni Syndrome patient with a novel HER2-V659E mutation. **Cancer Discovery**. 2013;3(11):1238-44 (\*co-corresponding authors).
- De Mattos-Arruda L, Tabernero J, **Seoane J**, Cortes J. Circulating tumour cells in early breast cancer. **Lancet Oncology**. 2012;13(9): e370; author reply e370.
- Ros-Blanco L, Anido J, Bosser R, Este J, Clotet B, Kosoy A, Ruiz-Avila L, Teixido J, **Seoane J\***, Borrell JI\*. NonCyclam Tetraamines inhibit CXC Chemokine Receptor Type 4 and target Glioma-Initiating Cells. **Journal of Medicinal Chemistry**. 2012 Sep 13;55(17):7560-70 (\*co-corresponding author).
- De Mattos-Arruda L, Cortes J, Santarpia L, Vivancos A, Tabernero J, Reis-Filho JS, **Seoane J**. Circulating Tumor Cells and Cell-Free DNA as Tools for Managing Breast Cancer. **Nature Reviews. Clinical Oncology**. 2013;10(7):377-89.
- Eichhorn PJ, Rodon L, Gonzàlez-Juncà A, Dirac A, Gili M, Martínez-Sáez E, Aura C, Barba I, Peg V., Prat A., Cuartas I, Jimenez J, García-Dorado D, Sahuquillo J, Bernardis R, Baselga J, **Seoane J**. USP15 stabilizes TGF- $\beta$  receptor I and promotes oncogenesis through the activation of TGF- $\beta$  signaling in glioblastoma. **Nature Medicine**. 2012;18(3):429-35. [see News and Views: Aggarwal K and Massagué J. Ubiquitin removal in the TGF- $\beta$  pathway. **Nature Cell Biology**. 2012; 18(3):429-35.
- Anido J, Sáez-Borderías A, Gonzàlez-Juncà A, Rodón L, Folch G, Carmona MA, Prieto-Sánchez RM, Barba I, Martínez-Sáez E, Prudkin L, Cuartas I, Raventós C, Martínez-Ricarte F, Poca MA, García-Dorado D, Lahn M, Yingling J, Rodón J, Sahuquillo J, Baselga J, **Seoane J**. TGF- $\beta$  receptor inhibitors target the CD44<sup>high</sup>/Id1<sup>high</sup> glioma-initiating cell population in human glioblastoma. **Cancer Cell**. 2010;18(6):655-68.
- Seoane J**. NO Signals from the Cancer Stem Cell Niche. **Cell Stem Cell**. 2010;6(2):97-8.
- Seoane J**. TGF- $\beta$  and cancer initiating cells. **Cell Cycle**. 2009;8(23):3787-8.
- Santamaria-Martínez A, Barquinero J, Barbosa-Desongles A, Hurtado A, Pinós T, **Seoane J**, Poupon MF, Morote J, Reventós J, Munell F. Identification of multipotent mesenchymal stromal cells in the reactive stroma of a prostate cancer xenograft by side population analysis. **Experimental Cell Research**. 2009;315(17):3004-13.
- Peñuelas S, Anido J, Prieto-Sánchez RM, Folch G, Barba I, Cuartas I, García-Dorado D, Poca MA, Sahuquillo J, Baselga J, **Seoane J**. TGF- $\beta$  increases glioma-initiating cell self-renewal through the induction of LIF in human glioblastoma. **Cancer Cell**. 2009;15(4):315-27.
- Eichhorn PJ, Gili M, Scaltriti M, Serra V, Guzman M, Nijkamp W, Beijersbergen RL, Valero V, **Seoane J**, Bernardis R, Baselga J. Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BE235. **Cancer Research**. 2008;68(22):9221-30.
- Baselga J, Rothenberg ML, Tabernero J, **Seoane J**, Daly T, Cleverly A, Berry B, Rhoades SK, Ray CA, Fill J, Farrington DL, Anne L, Yingling JM, Lahn M, Arteaga C, Carducci M. TGF- $\beta$  signaling related markers in cancer patients with bone metastasis. **Biomarkers**. 2008;13(2):217-36.
- Seoane J**. The TGF- $\beta$  pathway as a therapeutic target in cancer. **Clinical and Translational Oncology**. 2008;10(1):14-9.
- Seoane J**. TGF- $\beta$  signaling in homeostasis and cancer. In: Jakowlew SB (ed.) *Cancer Drug Discovery and Development: Transforming Growth Factor-Beta in Cancer Therapy, Vol. 1: Basic and Clinical Biology*. 1st ed. Totowa, NJ: **Humana Press**; 2008. pp 23-35.

- Bruna A, Darken RS, Rojo F, Ocaña A, Peñuelas S, Arias A, Paris R, Tortosa A, Mora J, Baselga J, **Seoane J**. High TGF- $\beta$ -Smad activity confers poor prognosis in glioma patients and promotes cell proliferation depending on the methylation of the PDGF-B gene. *Cancer Cell*. 2007;11(2):147-60.
- Seoane J**. Escaping from the TGF- $\beta$  anti-proliferative control. *Carcinogenesis*. 2006;27(11):2148-56.
- Gomis RR, Alarcón C, He W, Wang Q, **Seoane J**, Lash A and Massagué J. A FoxO-Smad synexpression group in human keratinocytes. *PNAS*. 2006;103(34):12747-52.
- Massagué J, **Seoane J**, Wotton D. Smad Transcription Factors. *Genes Development*. 2005;19(23):2783-810.
- Seoane J**, Le H-V, Shen L, Anderson SA, Massagué J. Integration of Smad and Forkhead Pathways in the Control of Neuroepithelial and Glioblastoma Cell Proliferation. *Cell*. 2004;117,211-223 (Cover) [see Preview: Arden KC. FoxO: Linking new signaling pathways. *Molecular Cell*. 2004;14(4):416-8].
- Calonge J, **Seoane J**, Massagué J. Opposite Smad and chicken ovalbumin upstream promoter transcription factor inputs in the regulation of the collagen VII gene promoter by transforming growth factor- $\beta$ . *Journal of Biological Chemistry*. 2004;279(22):23759-65.
- Seoane J**. p21(WAF1/CIP1) at the Switch Between the Anti-Oncogenic and Oncogenic Faces of TGF- $\beta$ . *Cancer Biology & Therapy*. 2004;3(2):226-7.
- Seoane J**, Le H-V, Massagué J. Myc suppression of p21(Cip1) Cdk inhibitor determines the outcome of the p53 response to DNA damage. *Nature*. 2002;419(6908):729-34 [see Preview: Vousden KH. Switching from life to death: the Miz-ing link between Myc and p53. *Cancer Cell*. 2002;2(5):351-2].
- Wu J-W, Hu M, Chai J, **Seoane J**, Huse M, Li C, Kyin S, Fairman R, Muir TW, Massague J, Shi Y. Crystal structure of a phosphorylated Smad2: Recognition of phosphoserine by the MH2 domain and insights on Smad function in TGF- $\beta$  signaling. *Molecular Cell*. 2001;8(6):1277-89.
- Seoane J**, Pouponnot C, Staller P, Schader M, Eilers M, Massagué J. TGF- $\beta$  influences Myc, Miz-1 and Smad to control the CDK inhibitor p15Ink4b. *Nature Cell Biology*. 2001;3(4):400-8.
- Staller P, Peukert K, Kiermaier A, **Seoane J**, Lukas J, Karsunky H, Moroy T, Bartek J, Massagué J, Hanel F, Eilers M. Repression of p15Ink4b expression by Myc through association with Miz-1. *Nature Cell Biology*. 2001;3(4):392-9.
- Hata A, **Seoane J**, Lagna G, Montalvo E, Hemmati-Brivanlou A, Massagué J. OAZ uses distinct DNA- and protein-binding zinc fingers in separate BMP-Smad and Olf signaling pathways. *Cell*. 2000;100(2):229-40.
- De la Iglesia N, Mukhtar M, **Seoane J**, Guinovart JJ, Agius L. The role of the regulatory protein of glucokinase in the glucose sensory mechanism of the hepatocyte. *Journal of Biological Chemistry*. 2000;275(14):10597-603.
- Warner BJ, Blain SW, **Seoane J**, Massagué J. Myc downregulation by transforming growth factor beta required for activation of the p15(Ink4b) G(1) arrest pathway. *Molecular and Cellular Biology*. 1999;19(9):5913-22 .
- Seoane J**, Barberà A, Telemaque-Potts S, Newgard SB, Guinovart JJ. Glucokinase overexpression restores glucose utilization and storage in cultured hepatocytes from male Zucker diabetic fatty rats. *Journal of Biological Chemistry*. 1999;274(45):31833-8.
- Seoane J**, Trinh K, O'Doherty RM, Gómez-Foix AM, Lange AJ, Newgard CB, Guinovart JJ. Metabolic impact of adenovirus-mediated overexpression of the glucose 6-phosphatase catalytic subunit in hepatocytes. *Journal of Biological Chemistry*. 1997;272(43):26972-7.

Guinovart JJ, Gómez-Foix AM, **Seoane J**, Fernández-Novell JM, Bellido D, Vilaró S. Bridging the gap between glucose phosphorylation and glycogen synthesis in the liver. *Biochemical Society Transactions*. 1997;25(1):157-60.

**Seoane J**, Gómez-Foix AM, O'Doherty RM, Gómez-Ara C, Newgard CB, Guinovart JJ. Glucose 6-phosphate produced by glucokinase, but not hexokinase I, promotes the activation of hepatic glycogen synthase. *Journal of Biological Chemistry*. 1996;271(39):23756-60.

O'Doherty RM, Lehman DL, **Seoane J**, Gómez-Foix AM, Guinovart JJ, Newgard CB. Differential metabolic effects of adenovirus-mediated glucokinase and hexokinase I overexpression in rat primary hepatocytes. *Journal of Biological Chemistry*. 1996;271(34):20524-30.

## Grants

---

Grantor: Institute of Health Carlos III – **FIS**

Title: Estudio del microambiente inmunosupresor del tumor cerebral

Role in the Project: Principal Investigator | 2023-2024

Grantor: **European Comission ERA-NET TRANSCAN-2**

Title: Next generation cancer immunotherapy: targeting the tumour microenvironment

Role in the Project: Role in the Project: Principal Investigator | 2023-2025

Grantor: **Hoffmann la Roche**

Title: Investigating the activity of a novel small molecule anticancer agent in PDX derived from MSI-H patients progressive to immunotherapies

Role in the Project: Role in the Project: Principal Investigator | 2022-2023

Grantor: **BBVA**

Title: 2nd BBVA Foundation Comprehensive Program of Cancer Immunotherapy & Immunology

Role in the Project: Role in the Project: Principal Investigator | 2022-2025

Grantor: **MINECO-RETOS**

Title: Early molecular nanoDIAGnostics of Brain tumors using Immune-PET (DIAGBI)

Role in the Project: Principal Investigator | 2021-2023

Grantor: **FERO**

Title: Biopsia líquida en cáncer cerebral pediátrico: Análisis de ADN circulante en el líquido cefalorraquídeo de pacientes pediátricos con meduloblastoma para ayudar a la detección caracterización y tratamiento del tumor cerebral en la recaída

Role in the Project: Principal Investigator | 2021-2023

Grantor: **AECC**

Title: Study of the impact of LIF and the tumor microenvironment on the immunomodulation of brain metastasis

Role in the Project: Principal Investigator | 2020-2024

Grantor: Institute of Health Carlos III – **FIS**

Title: "Estudio del microambiente inmunosupresor del tumor cerebral"

Project Reference: PI19/00318

Role in the Project: Principal Investigator | 2019-2021

Grantor: **Generalitat de Catalunya – Departament de Salut**

Title: "An anti-LIF therapeutic antibody, as a potential treatment for CoVid19"

Project Reference: COVID19-PoC

Role in the Project: Principal Investigator | 2020

Grantor: Agència de Gestió d'Ajuts Universitaris i de Recerca (**AGAUR**) Servei General de Recerca (SGR).

Title: "Ajuts de Suport a la recerca - Grups de Recerca Consolidats"

Role in the project: Principal Investigator | 2020-2023

Grantor: **Fundació Catalunya La Pedrera**

Title: "Programa joves i ciència"

Role in the Project: Principal Investigator | 2019 – 2020

Grantor: **FERO**

Title: "Caracterización molecular mediante el estudio del ADN circulante en líquido cefalorraquídeo para la mejora del tratamiento del tumor cerebral pediátrico, meduloblastoma".

Role in the Project: Principal Investigator | 2019-2020

Grantor: **Fundación ARECES.**

Title: "Identification of novel immunotherapeutic targets in lung and melanoma brain metastases"

Role in the Project: Principal Investigator | 2019-2022

Grantor: **BBVA**

Title: "Impact of the brain tumor microenvironment on the response of brain malignancies to immunotherapies".

Role in the Project: Principal Investigator | 2018

Grantor: Agència de Gestió d'Ajuts Universitaris i de Recerca (**AGAUR**) Servei General de Recerca (SGR).

Title: "Ajuts de Suport a la recerca - Grups de Recerca Consolidats"

Project Reference: 2017SGR528

Role in the project: Principal Investigator | 2017-2020

Grantor: Asociación Española Contra el Cáncer (**AECC**)

Title: "Study of the molecular mechanisms involved in primary (glioblastoma) and secondary (metastasis) brain tumors to identify novel therapeutic targets and anti-cancer agents, biomarkers to select treatments and novel non-invasive methods for molecular diagnosis.

Project Reference: GCTRA16015SEDA

Role in the Project: Principal Investigator | 2017-2022

Grantor: **IBEC-La Caixa**

Title: "Understanding and measuring mechanical tumor properties to improve cancer diagnosis, treatment, and survival: Application to liquid biopsies"

Role in the Project: Principal Investigator | 2017-2020

Grantor: Institute of Health Carlos III – **FIS**

Title: "Identificación de mecanismos de resistencia a tratamiento a través del estudio de la heterogeneidad intratumoral en glioblastoma"

Project Reference: Ref. PI16/01278

Role in the project: Principal Investigator | 2017-2019

Grantor: Institute of Health Carlos III – **FIS**

Title: "CIBER – Área Temática: Characterization and therapeutic use of stem cells and organoids in cancer"

Project Reference: Ref. CB16/12/00450

Role in the project: Principal Investigator | 2017-2018

Grantor: **FERO**

Title: "Caracterización molecular de los tumores cerebrales pediátricos mediante el estudio del DNA circulante en sangre y líquido cefalorraquídeo"

Role in the project: Principal investigator | 2015-2018

Grantor: **MINECO-RETOS**

Title: "Desarrollo de un fármaco innovador y personalizado para el tratamiento del cáncer que reactiva el sistema inmune contra el tumor y elimina las células madre tumorales"

Project Reference: RTC-2015-3771-1

Role in the project: Principal Investigator | 2015-2018

Grantor: European Research Council (**ERC**) Proof of Concept Grant

Title: "Development of a more effective and safer therapeutic antibody for cancer treatment with a dual mechanism of action to eliminate CSCs and reactivate the tumour's immune system". CSC-IS

Project reference: 665671

Role in the project: Principal Investigator | 2015-2016

Grantor: **MINECO-RETOS**

Title: "MSC-1, un fármaco innovador y personalizado para el tratamiento del cáncer con un doble mecanismo de acción: ataca las células madre tumorales y reactiva el sistema inmune del tumor".

Role in the project: Principal Investigator | 2014-2017

Grantor: Agència de Gestió d'Ajuts Universitaris i de Recerca (**AGAUR**)

Title: "Servei General de Recerca (SGR). Grups de Recerca Consolidats"

Project Reference: 2014SGR1335

Role in the project: Principal Investigator | 2014-2017

Grantor: Institute of Health Carlos III – **FIS**

Title: "Heterogeneidad intra-tumoral en glioblastoma. Implicaciones terapéuticas".

Project Reference: PI13/02661

Role in the project: Principal Investigator | 2014-2016

Grantor: The **Dr. Josef Steiner Cancer Research Foundation**

Title: "Molecular mechanisms implicated in glioblastoma and glioma-initiating cells. Identification of therapeutic targets and biomarkers of response to treatments against glioblastoma".

Role in the project: Principal Investigator | 2013-2017

Grantor: Institute of Health Carlos III – **FIS**

Title: "Red Temática de Investigación Cooperativa del Cáncer (RTICC)"

Project Reference: RD12/0036/0043

Role in the project: Principal Investigator | 2013-2017

Grantor: **Innovative Medicine Initiative-IMI**

Title: "Study of the CD44 high cancer stem cells".

Role in the project: Principal Investigator | 2013-2016

Grantor: European Research Council (**ERC**) Proof of Concept Grant

Title: "Targeting Cancer Stem Cells (CSC) for the development of more effective treatments to cure cancer patients"

Project reference: 324592

Role in the project: Principal Investigator | 2012-2013

Grantor: **CERCA** (Agency for the Research Centres of Catalonia) – Prova't Grant

Title: "Use of peptide shuttles for the delivery of monoclonal antibodies across the blood-brain barrier in brain tumours"

Role in the project: Principal Investigator | 2012-2014

Grantor: European Commission, Marie Curie International Reintegration Grant

Title: "Role of Notch signaling pathway in Glioma Stem Cells"

Role in the project: Principal Investigator | 2012-2014

Grantor: Institute of Health Carlos III – **FIS**

Title: "Estudio de los mecanismos moleculares implicados en la génesis del glioma y estudio de las células madre tumorales"

Project Reference: PI10/01848

Role in the project: Principal Investigator | 2011-2015

Grantor: Agencia de Gestió d'Ajuts Universitaris i de Recerca (**AGAUR**)  
 Title: "Proyecto relacionado con Beca postdoctoral del programa Beatriz de Pinos"  
 Role in the Project: Principal Investigator | 2010-2012

Grantor: Asociación Española Contra el Cáncer (**AECC**)  
 Title: "Mecanismos moleculares implicados en la génesis del glioma y estudio de las células madre tumorales. Identificación de nuevas dianas terapéuticas y marcadores para estratificación de pacientes y respuesta a fármacos"  
 Role in the project: Principal Investigator | 2010-2015

Grantor: Asociación Española Contra el Cáncer (**AECC**)  
 Title: "Function of the TGF-B, PI3K and JAK-STAT signalling pathways in glioma initiating cells".  
 Role in the Project: Principal Investigator | 2010-2014

Grantor: Ministry of Science and Innovation (**MICINN**)  
 Title: "EMBO YIP"  
 Project Reference: SAF2008-04778-E  
 Role in the project: Principal Investigator | 2009-2013

Grantor: Ministry of Science and Innovation (**MICINN**)  
 Title: "An integrated approach to post-transcriptional regulation of gene expression and its role in human disease"  
 Project Reference: CSD2009-00080  
 Role in the project: Principal Investigator | 2009-2014

Grantor: Agencia de Gestió d'Ajuts Universitaris i de Recerca (**AGAUR**)  
 Title: "Servei General de Recerca (SGR). Suport a Grups de Recerca de Qualitat"  
 Project Reference: 2009SGR504  
 Role in the project: Principal Investigator | 2009-2014

Grantor: European Research Council (**ERC**) Starting Grant  
 Title: "Molecular mechanisms of glioma genesis and progression"  
 Project reference: 205819-Glioma  
 Role in the project: Principal Investigator | 2008-2014

Grantor: Institute of Health Carlos III – FIS (**Ministry of Science and Innovation-MICINN**)  
 Title: "Papel del TGF- $\beta$  en la capacidad de auto-regeneración de las células madre de glioma"  
 Project Reference: PI070648  
 Role in the project: Principal Investigator | 2008-2011

Grantor: Association for International Cancer Research (**AICR**)  
 Title: "Role of FoxG1 in glioma"  
 Role in the project: Principal Investigator | 2006-2009

Grantor: Institute of Health Carlos III – FIS  
 Title: "Estudio de los mecanismos moleculares implicados en la génesis de glioma y estudio de las células madre tumorales"  
 Project Reference: PI040766  
 Role in the project: Principal Investigator | 2005-2008

Grantor: **European Commission, Marie Curie International Reintegration Grant**  
 Title: "Molecular mechanisms of gliomagenesis"  
 Project Reference: 017121-Glioma  
 Role in the project: Principal Investigator | 2005-2007

---

#### Participation in Research Contracts

Grantor: **Hoffmann-La Roche, Ltd.**  
 Title: ""  
 Principal Investigator: Joan Seoane | 2022-2023

Grantor: **AstraZeneca**  
 Title: "Identification of biomarkers to predict response to LIF inhibitors and Search for therapeutic compounds to combine with anti-LIF agents"  
 Principal investigator: Joan Seoane | 2021-2022

Grantor: **Roche/Glycart.**  
 Title: "Study of the impact of EGFRVIII intratumor heterogeneous expression before and after standard of care treatment on the response to EGFRVIII TCB in glioblastoma"  
 Principal Investigator: Joan Seoane | 2021-2022

Grantor: **Hoffmann-La Roche, Ltd.**  
 Title: "Deciphering mechanism of early disease relapse in BRAF mutant brain metastatic melanoma".  
 Principal Investigator: Joan Seoane | 2019-2022

Grantor: **Mosaic Biomedicals**  
 Title: "Assess whether the presence of high levels of LIF in the tumor can predict resistance to CPI"  
 Principal Investigator: Joan Seoane | 2019

Grantor: **Roche Glycart AG**  
 Title: "Preclinical Study of EGFRVIII TCBs in GBM"  
 Principal Investigator: Joan Seoane | 2018-2023

Grantor: **Mosaic Biomedicals**  
 Title: "Identify PD biomarkers and biomarkers to predict response to MSC1 treatment"  
 Principal Investigator: Joan Seoane | 2018-2019

Grantor: **Ridgeline Therapeutics, GmbH**  
 Title: "Test Ridgeline compounds in VHIO's PDX model and molecular characterization of HNSCC tissue samples"  
 Principal Investigator: Joan Seoane | 2017-2019

Grantor: **Mosaic Biomedicals**  
 Title: "Preclinical evaluation of MOSAIC's MSC-1 antibody"  
 Principal investigator: Joan Seoane | 2016-2017

Grantor: **Mosaic Biomedicals**  
 Title: "Preclinical evaluation of MOSAIC's MSC-1 antibody"  
 Principal investigator: Joan Seoane | 2015-2018

Grantor: **AstraZeneca**  
 Title: "Defining clinically actionable genetic alterations in DNA repair with in vivo response to the PARP inhibitor Olaparib"  
 Principal investigator: Joan Seoane | 2014-2017

Grantor: **Mosaic Biomedicals**  
 Title: "Preclinical evaluation of MOSAIC's MSC-1 antibody"  
 Principal investigator: Joan Seoane | 2014-2017

Grantor: **Eli Lilly**  
 Title: "Analysis of the TGF-  $\beta$  and type C signature in colorectal cancer"  
 Principal investigator: Joan Seoane | Jan 2015-Sept 2015

Grantor: **ISARNA Therapeutics GmbH**  
 Title: "Preclinical Evaluation of Isarna Next Generation Oligos (NGOs)"

Principal Investigator: Joan Seoane | 2013 - 2018

Grantor: **Novartis**

Title: "Therapeutic inhibition of the oncogenic Wnt/beta-catenin pathway"

Equipo investigador: Joan Seoane, Ana Vivancos, Héctor García Palmer | 2013 –2015

Grantor: **Eli Lilly**

Title: "Effect of the T $\beta$ RI/BMPRI dual inhibitor on glioblastoma and glioma-initiating cells"

Principal Investigator: Joan Seoane | 2011- 2017

Grantor: **Janus**

Title: "Effect of CXCR4 inhibitors on glioma initiating cells"

Principal Investigator: Joan Seoane | 2010

Grantor: **Novartis**

Title: "Effect PI3K inhibitors on glioma and glioma initialing cells"

Principal Investigator: Joan Seoane | 2009- 2012

Grantor: **Eli Lilly**

Title: "Preclinical studies with the TGF- $\beta$  receptor I inhibitor LY02109761"

Principal Investigator: Joan Seoane | 2006 - 2010

Grantor: **Merck Sharp and Dohme**

Title: "Role of TGF- $\beta$  in neuroprogenitor self-renewal"

Principal Investigator: Joan Seoane | 2005 - 2008

## Patents

---

Title: **Novel Use of Quinazolinone Compound for the Treatment of Cancer**

Application n./ Patent N: 212063336.6

Licensed to F. Hoffmann-La Roche AG

Register Date: November 4<sup>th</sup>, 2021

Title: **Methods for Improving Response to Anti-LIF Antibody Treatment in Individuals with Cancer**

Application n./Patent N: US non-provisional and PCT filling due 6/18/2019

Licensed to Mosaic Biomedicals, S.L.U et al.

Register Date: June 18<sup>th</sup>, 2018

Title: **Combination of LIF Inhibitors and Platinum-based Antineoplastic Agents for Use in Treating Cancer**

Application n./Patent N: US non-provisional and PCT filling due 6/18/2019

Licensed to Mosaic Biomedicals, S.L.U et al.

Register Date: June 18<sup>th</sup>, 2018

Title: **Methods of Quantifying LIF and Uses Thereof**

Application n./Patent N: US non-provisional and PCT filling due 6/18/2019

Licensed to Mosaic Biomedicals, S.L.U et al.

Register Date: June 18<sup>th</sup>, 2018

Title: **Antibodies against LIF and dosage forms thereof.**

Application n./Patent N: US non-provisional and PCT filling due 5/14/2019

Licensed to Mosaic Biomedicals, S.L.U et al.

Register Date: May 14<sup>th</sup>, 2018

Title: **Combination Of Lif Inhibitors And Pd-1 Axis Inhibitors For Use In Treating Cancer.**

Application N./Patent N: 18382248.5-1111

Licensed to Mosaic Biomedicals, S.L.U et al.



Register Date: April 12<sup>th</sup>, 2018

Title: **Antibodies Against LIF And Uses Thereof**

Application N./Patent N.: EP16382617.5

Licensed to Mosaic Biomedicals, S.L.

Register Date: December 19<sup>th</sup>, 2016.

Title: **Agents For The Treatment Of Diseases Associated With Undesired Cell Proliferation.**

Application N./ Patent N.: P12417EP00

Licensed to Mosaic Biomedicals, S.L.

Register Date: November 27<sup>th</sup>, 2015.

Title: **Antibody Recognizing Human Leukaemia Inhibitory Factor (LIF) And Use Of Anti-LIF Antibodies In The Treatment Of Diseases Associated With Unwanted Cell Proliferation.**

Application N./ Patent N.: EPA1038049.6

Licensed to Mosaic Biomedicals, S.L.

Register Date: April 5<sup>th</sup>, 2010.

Title: **Therapeutic Agents For The Treatment Of Diseases Associated With Undesired Cell Proliferation.**

Application N./ Patent N.: ESA200900928

Licensed to Mosaic Biomedicals, S.L.

Register Date: April 3<sup>rd</sup>, 2009.

#### **Other activities**

---

- **External evaluator** ERC grants (2021-)
- **External evaluator** Polish Center for Technology Development (PORT) (2021-)
- **Faculty member** of the "Cancer Research" Faculty Group, European Society for Medical Oncology (ESMO), 2015-present.
- **Reviewer** of the following journals: Nature, Cell, Nature Cell Biology, Cancer Cell, Cell Stem Cell, EMBO Journal, Journal of Chemistry, Carcinogenesis, Nucleic Acids Research, Journal of Cell Biology, Oncogene, Cancer Research, Clinical Cancer Research, Neuro-Oncology.
- **Member of the Scientific Committee**, Fundación Seve Ballesteros, 2013 -2016
- **Founder and Chairman** of Mosaic Biomedicals, May 2012. The company has received the following awards:
  - **BioExit 2017** (CataloniaBio) | March 2017
  - **Mejor Proyecto Emprendedor en Biotecnología** (ASEBIO, Genoma España, SEBiot, SEBBM) | 2012
  - **Mejor Proyecto en Biotecnología de España** (FECyT) | 2012
  - **Emprendedor XXI** (La Caixa) | June 2012
- **Local Chair** organizer of the 22nd Biennial Congress of the European Association for Cancer Research (EACR22), Barcelona, 2012.
- **Member of the Scientific Advisory Board** for the Cancer Research UK Manchester Institute 2016-2020
- **Chairman** of the EACR Conference Series meetings 2014-2019
- **Member of the ESMO Translational Research and Personalized Medicine Working Group**, 2016-2020.

- **Co-Chairperson organizer** of the Conference: Patient-Derived Cancer Models: Present and Future Applications from Basic Science to the Clinic, organized by the American Association for Cancer Research (**AACR**). February 11-14, 2016. New Orleans, LA.
- **Member of the Editorial Board** of Molecular Oncology, 2016 -
- **Chair & Organizer** of the EACR Conference: 'Defence is the Best Attack: Immuno-Oncology Breakthroughs', Barcelona, Spain, October 9-11<sup>th</sup>, 2017, March 11-13<sup>th</sup>, 2019 and February 16<sup>th</sup>-17<sup>th</sup>, 2021.
- **Member of the Scientific Steering Committee** for ESMO Madrid 2017 Conference.
- **Interviewed** for [ESMO Perspectives](#) (the ESMO Digital Magazine): Patient-Derived Tumour Models: The Clinic Mimics. Issue 3, 2017.
- **Member of the Scientific Steering Committee** for ESMO Munich 2018 Congress.
- **Chair & Organizer** of the EACR Conference: LIF As We Know It: From Basic Science to Clinical Trials. Barcelona, Spain, May 28th-29th, 2018.
- **Member of the Executive and Scientific Committee** organizer of the 25th Biennial Congress of the European Association for Cancer Research, Amsterdam, The Netherlands, June 30<sup>th</sup> -July 3<sup>rd</sup>, 2018.
- **Member** of the Bosarge Family Foundation-Waun Ki Hong Scholar Award for Regenerative Cancer Medicine **Scientific Review Committee** (from AACR) since 2019.
- **Member of the Scientific Committee** organizer of ESMO 2019 Congress in partnership with the EACR, Barcelona, Spain, September 26<sup>th</sup> – 30<sup>th</sup>, 2019.
- **Member of the Executive and Scientific Committee** organizer of EACR2020 Congress, Torino, Italy, June 17<sup>th</sup>-20<sup>th</sup>, 2020.
- **Member of the Scientific Committee** organizer of ESMO2020 Congress, Madrid, Spain, September 18<sup>th</sup>-22<sup>nd</sup>, 2020.
- **Faculty member at the Grand Challenge International Consultation Workshop** organized by Fundación de la AECC & Cancer Research UK, Madrid, Spain, 8th July 2019.
- **Interviewed for ESMO Society News:** Implications and future of targeted methylation analysis of cfDNA and its role in the early detection of tumours. A discussion with Professor Joan Seoane. 2020 April 3<sup>rd</sup>.
- **Member of the Scientific Committee** organizer of EACR2022 Congress, Sevilla, Spain, June 20<sup>th</sup>-23<sup>rd</sup> 2022.
- **Invited Speaker** at the **World Cancer Research Day** Virtual Event Worldwide, September 22<sup>nd</sup>, 2021. This event is a global initiative coordinated jointly by 10 organisations: American Association for Cancer Research (AACR), American Society of Clinical Oncology (ASCO), Asociación Española Contra el Cáncer (AECC), Associazione Italiana per la Ricerca sul Cancro (AIRC), Cancer Research UK (CRUK), European Association for Cancer Research (EACR), European Society for Medical Oncology (ESMO), International Agency for Research on Cancer (IARC), National Institutes of Health (NIH), National Cancer Institute (NCI) AND Union for International Cancer Control (UICC).
- **Invited Speaker** at the **BNEW (Barcelona New Economy Week) SCIENCE: BHEALTH - "Buscando soluciones para nuestra salud: un paso más allá gracias a la ciencia y la tecnología"**. Barcelona October 6th, 2021.
- **Faculty member at the Grand Challenge International Consultation Workshop** organized by Fundación de la AECC & Cancer Research UK, Madrid, Spain, November 2022.
- **Invited Speaker** at the **DEBAT 4** (Universitat Pompeu Fabra). Barcelona, October 18<sup>th</sup>, 2021

- **Invited Speaker** at the **European Research Council (ERC)** virtual event within the Excellent Science Pillar framework of the Europe Horizon Program 2021-2027. October 26<sup>th</sup>, 2021.
- **Invited Speaker** at **Semana de la Ciencia y la Innovación**, Vall d'Hebron Hospital Campus, November 15<sup>th</sup>, 2021.
- **Chair** at the **ASEICA Educational Symposium 2021**. Session 2: Immunomodulation and Cancer. Virtual event. November 24<sup>th</sup>, 2021.
- **Mentor** of the "**Programa Talents**"2020, **Fundació Catalunya La Pedrera**, Diploma Ceremony, Barcelona, Spain, April 4<sup>th</sup>, 2022
- **Chair** "Symposium: Dynamic Biology of Tumour under Therapy ", EACR Congress 2022, Sevilla, Spain, June 22<sup>nd</sup> 2022.

### Doctoral Theses supervised

---

*"Interrogating resistance mechanisms to PD-1 blockade therapy".*

Universitat Autònoma de Barcelona (UAB), Spain.

Doctoral Student: Davis Yuris Torrejón Castro – Dissertation date: 18 June 2021.

*"Role of HLA-G in shaping Natural Killer cell biology in cancer".*

Universitat de Barcelona (UB), Spain.

Doctoral Student: Ester Arroba - Dissertation date: 10 February 2021.

*"The Oncogenic of LIF function in glioblastoma".*

Universitat de Barcelona (UB), Spain.

Doctoral Student: Ada Sala Hojman - Dissertation date: 15 July 2016

*"Genomic characterization of brain malignancies through liquid biopsies: The cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma".*

Universitat Autònoma de Barcelona (UAB), Spain

Doctoral Student: Leticia de Mattos Arruda - Dissertation date: 29 June 2016

*"FOXG1 confers resistance to PI3K inhibitors through repressing FOXO activity in glioma".*

Universitat de Barcelona (UB), Spain

Doctoral student: Gerard Folch - Dissertation date: 26 January 2016

*"Study of the molecular mechanisms implicated in the TGF-Beta oncogenic effect in glioma."*

Universitat de Barcelona (UB), Spain

Doctoral student: Alba González Juncà - Dissertation date: 15 November 2013

*"Hyperactivation of the TGF-beta signaling pathway in glioblastoma: mechanisms and consequences."*

Universitat de Barcelona (UB), Spain

Doctoral student: Laura Rodón Ahnert - Dissertation date: 28 November 2012

*"Study of the TGFβ/PDGF-B axis in lung adenocarcinoma."*

Universitat de Barcelona (UB), Spain

Doctoral student: Francisco Miguel Torres Grande - Dissertation date: 8 June 2011

### Teaching experience in courses and seminars for university

---

**2022**

Master Oficial en Farmacología  
*Farmacológica*  
 Universitat Autònoma de Barcelona (UAB).  
 Facultat de Veterinària  
 Barcelona, Spain | 17th November 2022

Master in Translational Biomedical Research VHIR 2022-23  
*From a clinical problem to a clinical trial. The LIF dilemma.*  
 Facultat de Medicina  
 Universitat Autònoma de Barcelona (UAB)  
 Barcelona, Spain | 4th November 2022

Biomedicina i Benestar Planetari- Universitat Pompeu Fabra (UPF)  
 Department of Medicine and Life Sciences.  
 Debat: Càncer i genòmica  
 Barcelona, Spain | 27th september, 2022

Màster Bioquímica, Biologia Molecular i Biomèdica (UAB) - Institut de Neurociències  
 Facultat de Medicina  
 Universitat Autònoma de Barcelona (UAB)  
 Barcelona, Spain | 18th february 2022

## 2021

Master Biomedicine VHIR  
 Oncology  
 Universitat Autònoma de Barcelona (UAB)  
 Fundació Institut de Recerca de l'Hospital Universitari Vall d'Hebrón (VHIR).  
 Barcelona, Spain | 9th December 2021

Master in Pharmacology  
*Farmacológica*  
 Facultat de Veterinària  
 Universitat Autònoma de Barcelona (UAB)  
 Barcelona, Spain | 5<sup>th</sup> November 2021

Master in Translational Biomedical Research VHIR 2021-22  
*From a clinical problem to a clinical trial. The LIF dilemma.*  
 Facultat de Medicina  
 Universitat Autònoma de Barcelona (UAB)  
 Barcelona, Spain | 28th October 2021

Master Bioquímica i Biologia Molecular (UAB) - Institut de Neurociències  
 Facultat de Medicina  
 Universitat Autònoma de Barcelona (UAB)  
 Barcelona, Spain | 15<sup>th</sup> February 2021

Master in Translational Biomedical Research: Neoplastic Diseases  
 Oncology Master (UAB) Vall d'Hebron University Hospital  
 Fundació Institut de Recerca de l'Hospital Universitari Vall d'Hebrón (VHIR).  
 Barcelona, Spain | 7<sup>th</sup> January 2021

## 2020

Máster Oficial en Farmacología  
*Farmacológica*

Universitat Autònoma de Barcelona (UAB).  
Barcelona, Spain | 3<sup>rd</sup> November 2020

*From a clinical problem to a clinical trial.*

Programa de Formació en Recerca per a Residents

Master In Translational Biomedical Research 2020-2021.

Vall d'Hebron Institut de Recerca (VHIR) + Universitat Autònoma de Barcelona (UAB)

Webinar | 27<sup>th</sup> October 2020

*LIF in cancer. From bench to clinical trial*

Master Bioquímica i Biologia Molecular (UAB) - Institut de Neurociències

Facultat de Medicina

Universitat Autònoma de Barcelona (UAB)

Barcelona, Spain | 19<sup>th</sup> February 2020

## 2019

Master in Translational Biomedical Research: Neoplastic Diseases 2019-2020

Vall d'Hebron Institut de Recerca (VHIR) + Universitat Autònoma de Barcelona (UAB)

Barcelona, Spain | 16th December 2019

Máster Oficial en Farmacología – Farmacológica

Universitat Autònoma de Barcelona (UAB).

Barcelona, Spain | 6<sup>th</sup> November 2019

*LIF. Potential therapeutic approach in PDAC*

Course: "Top Highlights in Pancreatic adenocarcinoma (PDAC)

Vall d'Hebron Hospital Universitari

Barcelona, Spain | 4<sup>th</sup> October 2019

*Bases Moleculares de Transducció de Senyals i del Càncer*

Master Bioquímica i Biologia Molecular (UAB) - Institut de Neurociències

Facultat de Medicina

Universitat Autònoma de Barcelona (UAB)

Barcelona, Spain | 22<sup>nd</sup> February 2019

From discovery to clinical trials. Designing new anti-cancer drugs

Course: Oncología Médica (UAB) Vall d'Hebron University Hospital

Vall d'Hebron Institut d'Oncologia (VHIO)

Barcelona, Spain | 24<sup>th</sup> January 2019

- TGF-beta y Gliomas  
Master en Oncología Molecular: Bases Moleculares del Cáncer  
Centro de Estudios Biosanitarios (CEB)  
Madrid, Spain | *Online Edition (2019-2020)*

## 2018

- Master in Translational Biomedical Research: Neoplastic Diseases  
Oncology Master (UAB) Vall d'Hebron University Hospital  
Fundació Institut de Recerca de l'Hospital Universitari Vall d'Hebrón (VHIR).  
Barcelona, Spain | 17<sup>th</sup> December 2018
- Molecular mechanisms involved in the genesis and progression of brain cancer

Master Biomedicine  
 Universitat de Barcelona (UB)  
 Barcelona, Spain | 30<sup>th</sup> November 2018

- Heterogeneidad intratumoral y su evolución en la progresión tumoral.  
 Implicaciones biológicas y clínicas.  
 Programa interdisciplinar de Patología Molecular Diagnóstica  
 Hospital Universitari Vall d'Hebron (HUVH)  
 Barcelona, Spain | 16<sup>th</sup> November 2018
- Máster Oficial en Farmacología – Farmacológica  
 Universitat Autònoma de Barcelona (UAB).  
 Barcelona, Spain | 9<sup>th</sup> November 2018
- “The role of tumour microenvironment in Immunotherapy”.  
 Medical Education Program on Immunotherapy  
 Vall d'Hebron Institute of Oncology (VHIO)  
 Barcelona, Spain | 17<sup>th</sup> May 2018
- *Máster en Oncología Molecular: TGF-Beta y gliomas*  
 Universidad Rey Juan Carlos I (URJC)  
 Centro de Estudios Biosanitarios (CEB)  
 Madrid, Spain | *Online Edition (2018-2019)*
- “Dealing with intra-tumor heterogeneity in brain cancer”  
 V Ciclo Seminarios Biomedicina  
 Instituto de Investigaciones Biomédicas Alberto Sols (IIBM) CSIC-UAM  
 Madrid, Spain | 21<sup>st</sup> february 2018
- Tumor heterogeneity - Módulo Señalización y Cáncer  
 Máster de Bioquímica y Biomedicina  
 Universitat Autònoma de Barcelona (UAB)  
 Barcelona, Spain | 9<sup>th</sup> february 2018

## 2017

- *Máster en Oncología Molecular: TGF-Beta y gliomas*  
 Universidad Rey Juan Carlos I (URJC)  
 Centro de Estudios Biosanitarios (CEB)  
 Madrid, Spain | *Online Edition (2017-2018)*
- Máster Oficial en Farmacología – Farmacológica  
 Universitat Autònoma de Barcelona (UAB)  
 Barcelona, Spain | 10<sup>th</sup> November 2017
- Master in Translational Biomedical Research: Neoplastic Diseases  
 Oncology Master (UAB) Vall d'Hebron University Hospital  
 Fundació Institut de Recerca de l'Hospital Universitari Vall d'Hebrón (VHIR).  
 Barcelona, Spain | 9<sup>th</sup> November 2017
- Intratumor heterogeneity in brain cancer  
 Università degli Studi di Torino  
 Seminar. Candiolo Cancer Institute IRCCS  
 Candiolo, Torino, Italy | 19<sup>th</sup> January 2017
- Master in Translational Biomedical Research: Neoplastic Diseases  
 Oncology Master (UAB) Vall d'Hebron University Hospital

Fundacio Institut de Recerca de l'Hospital Universitari Vall d'Hebron (VHIR)  
Barcelona, Spain | 10<sup>th</sup> January 2017

## 2016

- Bases biològiques del càncer (II) – Bases moleculars del procés de disseminació.  
Licenciatura Mèdica: Assignatura Oncologia Mèdica  
Universitat Autònoma de Barcelona (UAB)  
Barcelona, Spain | 1<sup>st</sup> December 2016
- Màster Oficial en Farmacologia – Farmacològica  
Universitat Autònoma de Barcelona (UAB)  
Barcelona, Spain | 11<sup>th</sup> November 2016
- *Máster* en Oncología Molecular: TGF-Beta y gliomas  
Centro Nacional de Investigaciones Oncológicas (CNIO)  
Centro de Estudios Biosanitarios (CEB)  
Madrid, Spain | *Online Edition (2016-2017)*
- Master in Translational Biomedical Research: Neoplastic Diseases  
Oncology Master (UAB) Vall d'Hebron University Hospital  
Fundació Institut de Recerca de l'Hospital Universitari Vall d'Hebrón (VHIR)  
Barcelona, Spain | 14<sup>th</sup> January 2016

## 2015

- *Máster* Oficial en Farmacología – Farmacològica  
Universitat Autònoma de Barcelona (UAB)  
Barcelona, Spain | 11<sup>th</sup> November 2015
- *Impacte* de la heterogeneïtat intratumoral sobre la progressió del càncer  
Seminar  
Universitat Autònoma de Barcelona (UAB).  
Barcelona, Spain | 4<sup>th</sup> November 2015
- Bases *biològiques* del cancer (II) – Bases moleculars del proceso de disseminación  
Licenciatura Mèdica: Assignatura Oncologia Mèdica  
Universitat Autònoma de Barcelona (UAB)  
Barcelona, Spain | 2<sup>nd</sup> November 2015
- *Bases Moleculares del Cáncer*  
Master en Oncología Molecular (on-site and online Edition)  
CNIO - Centro de Estudios Biosanitarios (CEB)  
Madrid, Spain | 18<sup>th</sup> September 2015
- *Curso* de Formación de Ensayos Clínicos en Oncología  
Seminar  
Fundacio Institut de Recerca de l'Hospital Univ. Vall d'Hebron (VHIR)  
Barcelona, Spain | 3<sup>rd</sup> July 2015
- *Principios* de Oncología Molecular I  
Licenciatura Mèdica  
Universitat Autònoma de Barcelona (UAB)  
Barcelona, Spain | 2015

## 2014

- Master in Translational Biomedical Research: Neoplastic Diseases  
Oncology Master (UAB) Vall d'Hebron University Hospital  
Fundacio Institut de Recerca de l'Hospital Univ. Vall d'Hebron (VHIR)  
Barcelona, Spain | 16<sup>th</sup> December 2014
- *Máster en Farmacologia*  
Máster  
Universitat Autònoma de Barcelona (UAB)  
Barcelona, Spain | 6<sup>th</sup> November 2014
- *Principios de Oncología Molecular I*  
Licenciatura Médica  
Universitat Autònoma de Barcelona (UAB)  
Barcelona, Spain | 22<sup>nd</sup> October 2014
- *Bases Moleculares del Cáncer*  
Master en Oncología Molecular (on-site and online Edition)  
CNIO - Centro de Estudios Biosanitarios (CEB)  
Madrid, Spain | 19<sup>th</sup> September 2014
- *Curso Breast Cancer Management. "Angiogénesis y cáncer"*  
Vall d'Hebron Institute of Oncology (VHIO)  
Barcelona, Spain | June 2014

## 2013

- *Principios de Oncología Molecular I*  
Licenciatura Médica  
Universitat Autònoma de Barcelona (UAB)  
Barcelona, Spain | 4<sup>th</sup> October 2013
- *Curso de Formación de Ensayos Clínicos en Oncología*  
Workshop  
Vall d'Hebron University Hospital  
Barcelona, Spain | July 2013
- *Bases Moleculares del Cáncer*  
Master en Oncología Molecular (on-site and online Edition)  
CNIO – Centro de Estudios Biosanitarios (CEB)  
Madrid, Spain | 5<sup>th</sup> July 2013

## 2012

- *Principios de Oncología Molecular I*  
Licenciatura Médica  
Universitat Autònoma de Barcelona (UAB)  
Barcelona, Spain | 8<sup>th</sup> October 2012
- *Curso "Anticuerpos Monoclonales en Cáncer de Mama. Optimizando estudios clínicos y sus resultados"*  
Workshop  
Hospital Valle de Hebrón Barcelona  
Barcelona, Spain | March 2012



- *Bases Moleculares del Cáncer*  
Master en Oncología Molecular  
CNIO – Centro de Estudios Biosanitarios (CEB)  
Madrid, Spain | 4<sup>th</sup> May 2012

## 2011

- *Bases Moleculares del Cáncer*  
Master en Oncología Molecular  
CNIO – Centro de Estudios Biosanitarios (CEB)  
Madrid, Spain | 11<sup>th</sup> March 2011
- *Curso “Anticuerpos Monoclonales en Cáncer de Mama. Optimizando estudios clínicos y sus resultados”*  
Workshop  
Hospital Valle de Hebrón Barcelona  
Barcelona, Spain | 12<sup>th</sup> May 2011

## 2010

- *Bases Moleculares del Cáncer*  
Master en Oncología Molecular  
CNIO – Centro de Estudios Biosanitarios (CEB)  
Madrid, Spain | 15<sup>th</sup> January 2010

## 2008

- *Bases Moleculares del Cáncer*  
Master en Oncología Molecular  
CNIO – Centro de Estudios Biosanitarios (CEB)  
Madrid, Spain | 14<sup>th</sup> November 2008

## 2007

- *Bases Moleculares del Cáncer*  
Master en Oncología Molecular  
CNIO – Centro de Estudios Biosanitarios (CEB)  
Madrid, Spain | 6<sup>th</sup> July 2007

## 2004

- *Paper del TGF-B en oncogénesis*  
Seminar  
Departament Bioquímica Campus Bellvitge Universitat de Barcelona (UB).  
Barcelona, Spain | 2004
- *Curso animales modificados genéticamente: presente y futuro en la investigación biomédica*  
Curso  
Universidad de Santiago de Compostela.  
Santiago de Compostela, Spain | 2004
- *Máster en Investigación Biomédica Traslacional: Oncology Diseases*  
Máster  
Fundacio Institut de Recerca de l'Hospital Univ. Vall d'Hebron (VHIR)  
Barcelona, Spain | 2004
- *Principios de Oncología Molecular I*

Licenciatura Médica  
 Universitat Autònoma de Barcelona (UAB)  
 Barcelona, Spain | 2004

## Invited Lectures and Oral Communications

---

### 2022

*-Impact of the tumor microenvironment on immunotherapy*

ASEICA- 18<sup>th</sup> International Congress  
 Facultade de Medicina e Odontoloxía  
 Santiago de Compostela | 16-18<sup>th</sup> November, 2022

*-Preclinical models for the identification of therapeutic targets and biomarkers to predict response to treatment in the context of brain tumors*

CIBERONC Retreat: Mecanismos de progresión tumoral  
 Santiago de Compostela | 18-19<sup>th</sup> November, 2022

*-LIF in cancer immunology and immunotherapy*

International Symposium  
 Translational and reverse-translational research in Cancer Immunotherapy  
 CUN/CIMA (Fundación Ramón Areces)  
 Madrid | 29-30<sup>th</sup> September, 2022

*-Tumor Microenvironment Heterogeneity*

*(Liquid biopsies to characterize the brain tumor microenvironment)*

*-Treatment-induced plasticities*

17<sup>th</sup> EANO MEETING (2022)  
 European Association of Neuro-Oncology (EANO)  
 Vienna (Austria) | 15-18<sup>th</sup> September 2022

*-From basic science to clinical trials, LIF, at the intersection of embryology of cancer*

*-The relevance of liquid biopsies, specifically, in brain cancer.*

EMBO FEB Lectures Course  
 Spetses (Greece) | 16-24<sup>th</sup> August, 2022

*-Brain Cancer (Primary and Metastatic tumours)*

Meet the Expert Session  
 EACR2022 Congress  
 Sevilla, Spain | 20-23<sup>rd</sup> June 2022

*Preclinical models for immunotherapies*

Educational Session  
 EACR2022 Congress  
 Sevilla, Spain | 20-23<sup>rd</sup> June 2022

*Nuevas Dianas y Terapias Moleculares en el Oligodendroglioma*

Jornada Oligodendroglioma - Oligospain: Un Nuevo Camino Frente Al Oligodendroglioma  
 Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC)  
 Córdoba, Spain | 15<sup>th</sup> June 2022

*Cerebrospinal fluid liquid biopsies in medulloblastoma and brain metastasis*

6<sup>th</sup> Quadriennial Meeting of the World Federation of Neuro-Oncology Societies (WFNOS 2022)  
 Seoul, Korea & Virtual Event | 26<sup>th</sup> March 2022

## 2021

*NCRI Virtual Series 'In conversations with Prof. Joan Seoane'*

National Cancer Research Institute (NCRI)

Virtual Event | 16<sup>th</sup> November 2021*Circulating Tumor DNA in Neuro-Oncology*16<sup>th</sup> EANO MEETING (2021)

European Association of Neuro-Oncology (EANO)

Virtual Event | 25-26<sup>th</sup> September 2021*LIF as a therapeutic target in pancreatic cancer*

Jornada Formativa Càncer de Pàncreas

Vall d'Hebron Institute of Oncology (VHIO)

Barcelona, España | 8<sup>th</sup> July 2021*Brain Cancer Metastasis*

EACR 2021 Virtual Congress

European Association for Cancer Research (EACR)

Virtual Event | 9-12<sup>th</sup> June 2021*LIF as a therapeutic target in cancer*

Partners of Choice Scientific Exchange

AstraZéneca

Virtual Event | 22-23<sup>rd</sup> April 2021*Immunomodulation in cancer and embryogenesis*

AACR Annual Meeting 2021

Virtual Event | 9-14<sup>th</sup> April, 2021*Cancer meets virus. LIF as a regulator of the innate immune response to antigens*

Vall d'Hebron Institut de Recerca (VHIR)

Webinar | 24<sup>th</sup> March 2021*TGF-beta, LIF and extended families*

ESMO TAT Virtual Congress 2021

European Society for Medical Oncology (ESMO)

Virtual Conference | 2<sup>nd</sup> March 2021*Tumor Immune Microenvironment in Brain Cancer*

EACR Defence is the Best Attack: Immuno-Oncology Breakthroughs

European Association for Cancer Research (EACR)

Virtual Conference | 16-17<sup>th</sup> February 2021*Novel therapeutic targets and monitoring tools in brain malignancies*

V Jornadas Anuales CIBERONC

CIBERONC – Instituto de Salud Carlos III

Virtual Meeting | 11<sup>th</sup> february 2021*Circulating tumour DNA from the cerebrospinal fluid allows the characterization and monitoring of medulloblastoma*

VI Simposio "Biopsia Líquida: El camino a la oncología de precisión"

Instituto de Investigaciones Sanitarias de Santiago de Compostela.

Virtual Meeting | 26<sup>th</sup> January 2021.

## 2020

*Perspectivas futuras en el diagnóstico molecular de los tumores primarios y metástasis del SNC: biopsia líquida*

XV Curso de Neuro-Oncología Médica – Grupo Español de Investigación en Neuro-Oncología (GEINO)  
Vall d'Hebron University Hospital  
Webinar | 24<sup>th</sup> -25<sup>th</sup> November 2020

*Investigación e innovación en cáncer para mejorar la supervivencia*

Semana de la Ciencia - Conferencia  
Fundación Científica de la AECC  
Webinar | 16<sup>th</sup> November 2020

*Liquid biopsy in brain cancer. Getting beyond blood.*

Key Note Presentation  
ISLB Congress in Liquid Biopsy 2020  
International Society of Liquid Biopsy (ISLB)  
Webinar | 30<sup>th</sup> October 2020

*Cancer meets virus. LIF as a regulator of the innate immune response to antigens*

Vall d'Hebron Institut de Recerca (VHIR)  
Webinar | 28<sup>th</sup> October 2020

*La biopsia líquida. Nuevo método diagnóstico.*

Jornada de Cancer de Mama  
AECC  
Webinar | 19<sup>th</sup> October 2020

*cfDNA in CNS tumors*

ESMO Virtual Congress 2020  
Educational Weekend  
Webinar | 17<sup>th</sup> October 2020

*The role of TGF- $\beta$  inhibition in colorectal cancer: new perspectives*

Tour d'Europe in Colorectal Cancer  
Vall d'Hebron University Hospital  
Virtual Meeting | 6-7<sup>th</sup> October 2020

*Novel therapeutic targets and monitoring tools in brain malignancies*

Seminar - Candiolo Cancer Institute  
University of Torino, Italy  
Webinar | 12<sup>th</sup> June 2020

*Liquid biopsies and novel therapeutic targets in brain primary tumours and metastasis.*

Virtual Meet the Expert, EACR  
Webinar | 29<sup>th</sup> May 2020

*Novel targets and biomarkers in primary and metastatic brain cancer*

Seminar  
Cancer Research UK (CRUK), Manchester UK  
Webinar | 27<sup>th</sup> March 2020

*Liquid Biopsy*

Second Zurich Brain Metastases Symposium  
University Hospital Zurich  
Zurich, Switzerland | 16<sup>th</sup> January 2020

## 2019

*Immunomodulation in embryogenesis and cancer*

ESMO Immuno-Oncology Congress 2019  
Geneva, Switzerland | 12<sup>th</sup> December 2019

*Oncology meets embryology. LIF in cancer, from the lab to the clinical trial*

Barcelona BioMed Conference: Immunotherapy beyond cancer. A cure for age-related diseases  
Barcelona, Spain | 18<sup>th</sup> November 2019

*El tumor cerebral: un gran reto para la investigación*

Jornada divulgativa sobre el tumor cerebral  
AECC

Barcelona, Spain | 12<sup>th</sup> November 2019

*Development of a novel agent (MSC-1) to reactivate an immune call by LIF blockade*

Immuno-Oncology Profiling Congress 2019

Palau de Congressos de Catalunya  
Barcelona, Spain | 30<sup>th</sup> October 2019

*LIF in cancer*

AACR-NCI-EORTC International Conference Molecular Targets and Cancer Therapeutics

Hynes Convention Center

Boston, Ma, USA | 29<sup>th</sup> October 2019

*Liquid Biopsy in Brain Tumors*

CIBER-BBN 2019 Annual Conference

Hotel SB Ciutat de Tarragona

Tarragona, Spain | 21<sup>st</sup> October 2019

*"Embryology meets Oncology. Role of LIF in glioblastoma"*

XVIII Congreso de la Sociedad Española de Biología Celular

Edificio Institutos Universitarios

Badajoz, Spain | 16<sup>th</sup> October 2019

*Basic science*

Poster Discussant

ESMO Congress 2019

Fira Gran Via Barcelona

Barcelona, Spain | 29<sup>th</sup> September 2019

*Innate immune system and anti-mitotic agents: Two fields getting together*

Special Session 1 – Chair and Speaker

ESMO Congress 2019

Fira Gran Via Barcelona

Barcelona, Spain | 27<sup>th</sup> September 2019

*Cell-free tumor DNA*

14<sup>th</sup> EANO Meeting

Centre de Congrès, CITÉ

Lyon, France | 20<sup>th</sup> September 2019

*The immunosuppressive role of LIF in cancer*

Canadian Cancer Immunotherapy Consortium meeting,

Mount Sinai Hospital

Toronto, Canada | 19<sup>th</sup> September 2019

*The oncogenic role of the cytokine LIF. Parallelisms between Oncology and Embryology*  
Seminar  
The Donnelly Centre, University of Toronto  
Toronto, Canada | 18<sup>th</sup> September 2019

*TGF $\beta$  Signaling and Immuno-oncology*  
I ASEICA-ASPIC INTERNATIONAL MEETING: Current Trends In Immunotherapy Research And Treatment  
Centro de Investigación del Cáncer  
Salamanca, Spain | 13<sup>th</sup> September 2019

*Sortides professionals a la Carrera Acadèmica I Investigadora*  
II Jornada d'Orientació Professional VHIR  
Vall d'Hebron Institut de Recerca  
Barcelona, Spain | 11<sup>th</sup> June 2019

*Liquid biopsies in brain cancer*  
Brain Tumor Meeting 2019  
Max Delbrück Communications Center  
Berlin, Germany | 24<sup>th</sup> May 2019

*Liquid biopsies from brain tumours*  
EACR-ESMO Liquid Biopsies 2019  
Centro Congressi Giovanni XXIII  
Bergamo, Italy | 15<sup>th</sup> May 2019

*Biology of Leukemia Inhibitory Factor (LIF) and role in cancer*  
Seminar  
Celgene Corporation  
Seattle, USA | 25<sup>th</sup> March 2019

*Embryology meets Oncology. The role of LIF in cancer*  
EACR Conference: Defence is the Best Attack 2nd Edition  
La Pedrera  
Barcelona, Spain | 12<sup>th</sup> March 2019

*Immunomodulation in embryogenesis and cancer*  
EACR Conference: Tracking Cancer 2019  
CosmoCaixa Science Museum  
Barcelona, Spain | 6<sup>th</sup> February 2019

## 2018

*"Embryology meets oncology. The immunomodulatory role of LIF in cancer"*  
Simposio Científico  
"VIII Centenario Universidad de Salamanca: Nuevos retos en investigación oncológica"  
Salamanca, Spain | 27<sup>th</sup> November 2018

*"Situació actual de la recerca oncològica"*  
XXXII Jornada d'avanços en la prevenció, el diagnòstic i el tractament del càncer (AECC)  
Facultat de Medicina de la UB  
Barcelona, Spain | 24<sup>th</sup> November 2018

*"Understanding the role of TGFbeta signalling in cancer"*  
NCRI Cancer Conference 2018  
Scottish Event Campus

Glasgow, UK | 6<sup>th</sup> November 2018

*“La lluita contra el càncer. Com vèncer un enemic heterogeni, canviant i parcialment desconegut”*

Aula de la Universitat a l'Abast

La Garriga, Barcelona, Spain | 30<sup>th</sup> October 2018

BCN Inspiracy Talks Interview

Cosmocaixa

Barcelona, Spain | 27<sup>th</sup> October 2018

*“CNS tumours” - Proffered Paper session*

ESMO 2018 Congress

Discussant

Messe Munich

Munich, Deutschland | 19<sup>th</sup> October 2018

*“LIF and the innate immune response. Linking embryology and cancer”*

1<sup>st</sup> Oncobell International Symposium

Hospital Duran i Reinalds

Barcelona, Spain | 21<sup>st</sup> September 2018

*“Embryology meets oncology. The immunomodulatory role of LIF in cancer”*

25th Biennial Congress of the European Association for Cancer Research (EACR)

RAI Convention Centre

Amsterdam, The Netherlands | 1<sup>st</sup> July 2018

*“General Conclusions & Award Presentation”*

LIF As We Know It: From Basic Science to Clinical Trials

Chair & Scientific Organizer

VHIO (Vall d'Hebron Institute of Oncology)

Barcelona, Spain | 29<sup>th</sup> May 2018

*“Immunomodulatory role of LIF in cancer”*

LIF As We Know It: From Basic Science to Clinical Trials

Chair & Scientific Organizer

VHIO (Vall d'Hebron Institute of Oncology)

Barcelona, Spain | 28<sup>th</sup> May 2018

· *“La complejidad de la vida. El càncer.”*

Pint Of Science Festival

Barcelona, Spain | 15<sup>th</sup> May 2018

*“The role of CDK along the mitotic process in normal and pathological condition”*

Co-Chair: ESMO Symposium on Signalling Pathways in Cancer 2018

Vall d'Hebron Institute of Oncology (VHIO)

Barcelona, Spain | 23<sup>rd</sup> March 2018

*“Implicaciones de la evolución de la heterogeneidad genética intratumoral en el tratamiento del càncer”.*

IV Simposio Nacional de Genómica Aplicada en Oncología

CNIO (Centro Nacional de Investigaciones Oncológicas)

Madrid, España | 20<sup>th</sup> March 2018

## 2017

*“Is there a role for targeting transforming growth-factor-b?”*

ESMO Immuno-oncology Congress 2017

Paexpo

Geneva, Switzerland | 10<sup>th</sup> December 2017

*“NGS y LCR: presente y futuro”*

IX Symposium GEINO 2017

Universidad de Málaga

Málaga, Spain | 30<sup>th</sup> November 2017

*“Molecular insights to glioblastoma progression and therapy resistance”*

1st ASEICA Educational Symposium

Facultad de Medicina, Universidad Autónoma de Madrid (UAM)

Madrid, Spain | 14<sup>th</sup> November 2017

*“Novel therapeutic targets in brain tumors”*

Defence is the Best Attack. Immuno-Oncology Breakthroughs

EACR Conference Series

La Pedrera

Barcelona, Spain | 9<sup>th</sup> October 2017

*“What can we learn from patient-derived models?”*

Special Symposium: Targeted therapy in neuro-oncology

ESMO 2017

IFEMA

Madrid, Spain | 10<sup>th</sup> September 2017

- *Translational Research: Proffered paper & Poster discussion  
Chair & Invited Lecturer*  
ESMO 2017  
IFEMA  
Madrid, Spain | 9<sup>th</sup> September 2017
- *“Oncology and research in Spain and beyond: Sharing knowledge about cancer”  
Special Event: AECC, ASEICA, EACR, ESMO and SEOM  
Invited Lecturer*  
El Prado Museum Auditorium  
Madrid, Spain | 7<sup>th</sup> September 2017
- *“The TGF- $\beta$  signaling in glioblastoma”*  
FASEB TGF-beta Conference  
Marriot Hotel  
Lisbon, Portugal | 11<sup>th</sup> July 2017
- *“Utilidad de la biopsia líquida en el diagnóstico del Glioblastoma y de las metástasis cerebrales”*  
Curso de Neuropatología. Avances en Patología Molecular e Inmunooncología en Neuropatología.  
XXVIII Congreso Nacional SEAP-IAP  
Palacio de Congresos de Valencia  
Valencia, Spain | 26<sup>th</sup> May 2017
- *“El conocimiento molecular del cáncer. Modelos animales”*  
Jornadas Iberoamericanas sobre cáncer de mama metastásico.  
Vall d’Hebron Institute of Oncology (VHIO)  
Barcelona, Spain | 15<sup>th</sup> May 2017
- *“Fighting cancer. Defeating an heterogeneous and changing enemy”*  
Inaugural conference.  
Institut de Biotecnologia i de Biomedicina.  
Barcelona, Spain | 9<sup>th</sup> May 2017



- *“Genomic intratumor heterogeneity and cancer resistance to treatment”*  
ICREA-FIJC 2017 Meeting  
Auditorium of the School of Medicine. University of Barcelona.  
Barcelona, España | 7<sup>th</sup> March 2017
- *“Evolving intratumor heterogeneity in primary and secondary brain malignancies”*  
CNIO Frontiers Meeting: “Primary and Secondary Brain Tumors”  
CNIO (Centro Nacional de Investigaciones Oncológicas)  
Madrid, España | 21<sup>st</sup> February 2017
- *“Evolving intratumor heterogeneity in brain tumors”*  
Symposium 5 - Distinguished Spanish speakers session  
Human Genome Meeting 2017  
Hotel Barceló Sants  
Barcelona, España | 6<sup>th</sup> february 2017

## 2016

- *“Biopsia líquida”*  
Heterogeneidad Tumoral: Implicaciones Clínicas en Glioblastomas.  
VIII Symposium Educacional GEINO 2016: Tratamiento de los Tumores Cerebrales  
Hospital Universitario Ramón y Cajal  
Madrid, España | 25<sup>th</sup> November 2016
- *“Detección de marcadores moleculares circulantes en biopsia líquida en el glioblastoma”*  
La Neuropatología y Nuevas Tecnologías  
LXVIII Reunión Anual de la Sociedad Española de Neurología  
Palacio de Congresos de Valencia  
Valencia, España | 18<sup>th</sup> November 2016
- *“Intratumor heterogeneity in cancer”*  
II Reunión de Investigación Traslacional en Melanoma  
Hospital Universitario Quirón Dexeus  
Barcelona, España | 3<sup>rd</sup> November 2016
- *Intratumor Heterogeneity*  
Cancer Immunotherapy  
NCT SummerSchool in Translational Cancer Research  
DKTK German Cancer Consortium  
Hotel Porto Bay Falesia  
Albufeira, Portugal | 28<sup>th</sup> October 2016
- *“Preclinical concepts of glioma”*  
XII Meeting of the European Association of Neuro-Oncology (EANO) and Educational Day  
Congress Center Rosengarten  
Mannheim, Germany | 13<sup>th</sup> October 2016
- *Translational research*  
Chair - Poster session  
ESMO 2016 Congress  
Bella Center Copenhagen Convention Center  
Copenhagen, Denmark | 10<sup>th</sup> October 2016
- *Patient derived models to select treatment*  
*Conclusions and clinical perspectives*  
Special Symposium: Using biomarkers to monitor the dynamics of tumor responses to therapy  
Chair & Speaker

ESMO 2016 Congress  
 Bella Center Copenhagen Convention Center  
 Copenhagen, Denmark | 10<sup>th</sup> October 2016

- *Conclusions and Clinical Perspectives*  
 Special Session: Will we ever conquer resistance?  
 Co-Chair & Speaker  
 ESMO 2016 Congress  
 Bella Center Copenhagen Convention Center  
 Copenhagen, Denmark | 8<sup>th</sup> October 2016
- *Basic science and translational research*  
 Chair & Discussant: Poster session  
 ESMO 2016 Congress  
 Bella Center Copenhagen Convention Center  
 Copenhagen, Denmark | 8<sup>th</sup> October 2016
- *"New therapeutic targets in glioblastoma"*  
 Novel targeted therapies  
 24<sup>th</sup> Biennial Congress of the European Association for Cancer Research  
 Manchester Central Convention Complex  
 Manchester, UK | 11<sup>th</sup> July 2016
- *"Glioblastoma microenvironment"*  
 Brain Tumors 2016 from Biology to Therapy  
 Nencki Institute of Experimental Biology  
 Warsaw, Poland | 27<sup>th</sup> June 2016
- *"Biomarkers of response to anti-TGF-beta agents in cancer".*  
 IT-LIVER Final Conference: "TGF-beta family in fibrosis and cancer"  
 IT-LIVER EU (Marie Curie 7<sup>th</sup> Framework Program)  
 Barcelona, Spain | 14<sup>th</sup> June 2016
- *"Evolving Intratumor Genomic Heterogeneity in Brain Cancer"*  
 EMBO Meeting Cellular signaling and Cancer therapy  
 Cavtat, Dubrovnik, Croatia | 29<sup>th</sup> May 2016
- *"Intratumor Heterogeneity and Clonal Evolution in Glioblastoma"*  
 VHIO Symposium: Towards Predictive Cancer Models  
 Barcelona, Spain | 26<sup>th</sup> May 2016
- *"Evolving intratumor genomic heterogeneity in brain cancer"*  
 Personalized Cancer Care meeting  
 Institute for Cancer Research  
 Oslo University Hospital  
 Oslo, Norway | 19<sup>th</sup> May 2016
- *"III Jornada Recerca i Empresa: Converses en Feedwork"*  
 Universitat de Barcelona (UB), Facultat de Psicologia  
 Recerca, Salut i Innovació"  
 Barcelona, Spain | 3<sup>rd</sup> May 2016
- *"Fighting cancer. How to defeat a multifaceted, fluctuating and partially unknown enemy"*  
 Master class.  
 Universitat de Vic (UVIC)  
 Vic, Barcelona, Spain | 20<sup>th</sup> April 2016

- *"Inmunoterapia en glioblastoma"*  
Preceptorship Inmunooncología  
UITM & MSD: Conceptos actuales de Inmunooncología Clínica y Traslacional  
Auditorium Cellex.  
Barcelona, Spain | 15<sup>th</sup> -16<sup>th</sup> February 2016
- *"Patient-derived xenograft models in glioblastoma "*  
Chair & Speaker  
AACR Patient-Derived Cancer Models: Present and Future Applications from Basic Science to the Clinic  
conference.  
Hyatt Regency New Orleans  
New Orleans, Louisiana | 13<sup>th</sup> February 2016
- *Plenary Session 5: Disease-specific PDX Models III*  
Chair  
AACR Patient-Derived Cancer Models: Present and Future Applications from Basic Science to the Clinic  
conference.  
Hyatt Regency New Orleans  
New Orleans, Louisiana | 13<sup>th</sup> February 2016

## 2015

- *"Cancer initiating cells in brain tumors"*  
8<sup>th</sup> Biennial Congress of the SETGyC  
Kursaal Congress Center  
San Sebastián, Spain | 5<sup>th</sup> November 2015
- *"El valor de la innovación en oncología"*  
XV Congreso SEOM  
Hotel Melia Castilla  
Madrid, Spain | 28<sup>th</sup> October 2015
- *"Research and development for brain tumour treatments – Thinking Outside the Box"*  
IBTA - Second World Summit of Brain Tumour Patient Advocates  
Meliá Sitges Hotel  
Sitges, Barcelona, Spain | 27<sup>th</sup> October 2015
- *"The TGF- $\beta$  pathway as a therapeutic target against cancer"*  
15<sup>th</sup> ASEICA International Congress  
Sevilla, Spain | 22<sup>nd</sup> October 2015
- *"Tumor cell heterogeneity"*  
3<sup>rd</sup> EurocanPlatform Summer School in Translational Cancer Research  
Hotel Porto Bay  
Falesia, Portugal | 14<sup>th</sup> October 2015
- *"TGF  $\beta$  and immunoresistance"*  
Ponencia. 1<sup>a</sup> Reunión Investigación Traslacional en Melanoma  
Hospital Universitario Quirón Dexeus  
Barcelona | 2<sup>nd</sup> October 2015
- *"Biological and clinical impact of intratumor heterogeneity"*  
15<sup>th</sup> Anniversary Cancer Research Center  
CSIC University of Salamanca  
Salamanca, Spain | 1<sup>st</sup> October 2015
- *"Impact of intratumor heterogeneity in glioblastoma relapse"*

European CanCer Organisation (ECCO) Congress  
Society Session: Clinical and Biological Implications of Intratumor Heterogeneity  
Vienna, Austria | 26<sup>th</sup> September 2015

- *"Evolution of the intratumor heterogeneity in glioblastoma in response to treatment"*  
II International Symposium on Clinical and Basic Investigation on Glioblastoma  
Plenary Session  
Universidad de Castilla – La Mancha. Campus de Toledo  
Toledo, España | 10<sup>th</sup> September 2015
- *"Impact of the intratumor genomic heterogeneity and evolution in the treatment of glioblastoma"*  
2<sup>nd</sup> EACR Special Conference on Cancer Genomics  
Session 3: Genomic Mechanisms of Resistance  
Churchill College, University of Cambridge  
Cambridge, UK | 30<sup>th</sup> June 2015
- *"ctDNA in CSF, characterization in brain tumors"*  
Workshop on Circulating Biomarkers in Cancer  
Circulating cancer biomarkers: Technical session  
EurocanPlatform  
Institute for Cancer Research, Oslo University Hospital, The Norwegian Radium Hospital  
Oslo, Norway | 18<sup>th</sup> May 2015
- *"Molecular mechanisms involved in glioblastoma"*  
Guest Speaker Seminar  
Cancer Research UK, Manchester Institute, The University of Manchester  
Manchester, UK | 29<sup>th</sup> January 2015
- *"Intratumor heterogeneity in brain tumors"*  
Cell Communication in Translational Research  
Weizmann Institute of Science-Vall d'Hebron Institute of Oncology Conference  
The David Lopatie Conference Centre, Weizmann Institute of Science  
Rehovot, Israel | 22<sup>nd</sup> January 2015

## 2014

- *"Hacia una nueva comprensión del cáncer y sus terapias"*  
Ciclo de debates y conferencias "Células madre: ¿un futuro sin enfermedades?"  
Centre de Cultura Contemporània de Barcelona (CCCB)  
Barcelona, Spain | November 2014
- *"La vía del TGF- $\beta$  como diana terapéutica contra el cáncer"*  
IV Ciclo Seminarios de Investigación (2014-15)  
Facultad de Medicina y Gerencia de Atención Integrada de Ciudad Real  
Ciudad Real, Spain | November 2014
- *"FoxG1 confers resistance to PI3K inhibitors"*  
Annual Meeting - PI3K: Paper en Fisiologia i Patologia  
Societat Catalana de Biologia  
Barcelona, Spain | October 2014
- *"The TGF- $\beta$  pathway as a therapeutic target"*  
23<sup>rd</sup> Biennial Congress of the European Association for Cancer Research (EACR)  
International Congress Centre Munich (ICM)  
Munich, Germany | 7<sup>th</sup> July 2014
- *"TGF- $\beta$ : A Prime Target for Cancer Immunotherapy"*

12<sup>th</sup> CIMT Annual Meeting - The Association for Cancer Immunotherapy  
Rheingoldhalle Main Congress Center  
Mainz, Germany | 7<sup>th</sup> May 2014

- *"The TGF- $\beta$  pathway as a therapeutic target in brain tumors"*  
Karolinska Institutet Stockholm  
Stockholm, Sweden | April 2014
- *"Intratumoral heterogeneity in glioblastoma"*  
AACR Special Conference on Cellular Heterogeneity in the Tumor Microenvironment  
The Westin Gaslamp Quarter  
San Diego, CA, USA | February-March 2014
- *"Targeting the TGF- $\beta$  pathway in brain tumors"*  
Biotech Research and Innovation Center (BRIC)  
University of Copenhagen  
Copenhagen, Denmark | January 2014

## 2013

- *"The TGF- $\beta$  pathway as a therapeutic target in brain tumors"*  
Stem Cells and Regenerative, Medicine Seminar Series  
An Interdisciplinary Approach to Stem Cell Science  
Faculty of Medicine, University of Geneva  
Geneva, Switzerland | November 2013
- *"Intra-Tumoral Heterogeneity in Brain Tumors"*  
17<sup>th</sup> Fritz Bender Foundation International Symposium: Progreso Hacia el Tratamiento Individualizado del Cáncer  
Vall d'Hebron Institute of Oncology (VHIO)  
Barcelona, Spain | November 2013
- *"The TGF- $\beta$  pathway as a therapeutic target"*  
IT LIVER Workshop: "Omics meet translational research"  
Marie-Curie ITN action "ITLiver"  
Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) - Societat Catalana de Biologia (SCB)  
Barcelona, Spain | September 2013
- *"Tumor Initiating Cell Population in Human Glioblastoma"*  
10<sup>th</sup> JIM Key Symposium: Taming the Cancer Cell  
Journal of Internal Medicine - Royal Swedish Academy of Science  
Stockholm, Sweden | September 2013
- *"Targeting TGF- $\beta$  in glioblastoma"*  
Conference TGF- $\beta$  Superfamily: Signaling in Development and Disease  
Federation of American Societies for Experimental Biology (FASEB)  
Colorado, USA | July 2013
- *"TGF- $\beta$  y gliomas"*  
Centro Nacional de Investigaciones Oncológicas (CNIO)  
Madrid, Spain | July 2013
- *"Mecanismos Moleculares del Cáncer"*  
Curso de Formación de Ensayos Clínicos en Oncología  
Vall d' Hebron University Hospital  
Barcelona, Spain | July 2013

- *“Heterogeneidad intratumoral en glioblastoma”*  
XI Ciclo de Seminarios  
Instituto de Biomedicina de Sevilla (IBiS)  
Hospital Universitario Virgen del Rocío  
Sevilla, Spain | *June 2013*
- *“Amilogénesis y cáncer”*  
Breast Cancer Management Course  
Vall d’Hebron Institute of Oncology (VHIO)  
Vall d’ Hebron University Hospital  
Barcelona, Spain | *June 2013*
- *“Intratumoral heterogeneity in glioblastoma”*  
Hospital Universitario Madrid Sanchinarro  
Madrid, Spain | *June 2013*
- *“The TGF- $\beta$  pathway as a therapeutic target in cancer”*  
Centro de Investigaciones Biológicas (CIB)  
Madrid, Spain | *May 2013*
- *“Modelling the behaviour of cancer stem cells”*  
5<sup>th</sup> Symposium on Anticancer Drug Discovery  
Pre-clinical models of cancer: Towards enhanced clinical relevance and predictivity  
Oncotest Institute for Experimental Oncology  
Freiburg, Germany | *April 2013*
- *“Functional analysis with patient-derived models. Getting close to the real tumor”*  
XXI Porto Cancer Meeting  
Auditorium of IPATIMUP (Institute of Molecular Pathology and Immunology of the University of Porto)  
Porto, Portugal | *April 2013*
- *“Cancer Stem Cells/Cancer-Initiating Cells: Signaling and Treatment Approaches”*  
AACR Annual Meeting  
Walter E. Washington Convention Center  
Washington DC, USA | *April 2013*
- *“The Transforming growth factor  $\beta$  as a therapeutic target in glioblastoma”*  
EORTC-EANO-ESMO Conference 2013  
Clarion Congress Hotel  
Prague, Czech Republic | *March 2013*

## 2012

- *“Regulation of the cell state of differentiation by TGF- $\beta$ ”*  
“Chromosomes, Stem Cells and Disease” Annual Meeting  
Parc de Recerca Biomédica de Barcelona (PRBB)  
Barcelona, Spain | *September 2012*
- *“Molecular Mechanisms of gliomagénesis”*  
Satellite event, FENS Forum 2012: Developmental Tumors of the Nervous System  
Hospital Sant Joan de Déu  
Barcelona, Spain | *July 2012*
- *“Translational research in glioblastoma: linking molecular characterization to treatment”*  
“Translating cancer research to personalized hospital treatment. Can it work?”  
“Cancer-initiating Cells in Glioblastoma”  
EARC22 - European Association for Cancer Research

Barcelona, Spain | July 2012

- *"Intra-tumoral heterogeneity in Glioblastoma"*  
Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)  
Barcelona, Spain | June 2012
- *"Angiogénesis en càncer de mama"*  
Course: "Anticuerpos Monoclonales en Càncer de Mama. Optimizando estudios clínicos y sus resultados"  
Vall d' Hebron University Hospital  
Barcelona, Spain | March 2012
- *"Expressió gènica i biologia del càncer"*  
Vall d' Hebron University Hospital  
Barcelona, Spain | March 2012
- *"TGF- $\beta$  y gliomas"*  
Centro Nacional de Investigaciones Oncológicas (CNIO)  
Madrid, Spain | May 2012
- *"Cancer-initiating cells in glioblastoma"*  
Cabimer - Centro Andaluz de Biología Molecular y Medicina Regenerativa  
Sevilla, Spain | March 2012
- *"Signalling pathways of cancer stem cells and molecular diagnosis of glioblastoma. Update and therapeutic implications"*  
VIII Jornada de Neuro-Oncología: El Glioblastoma  
Barcelona, Spain | February 2012

## 2011

- *"Etiología y Tratamiento de los Tumores Cerebrales"*  
Curso de Neurociencia  
Institut de Recerca Biomèdica de Lleida  
Lleida, España | November 2011
- *"The cancer stem cell niche"*  
AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics  
San Francisco, USA | November 2011
- *"TGF- $\beta$  and Cancer-Initiating Cells. Targeting the root of cancer"*  
XIII Congreso Nacional ASEICA  
Salamanca, Spain | September 2011
- *"TGF- $\beta$  as a therapeutic target in glioblastoma. Targeting glioma-initiating cells"*  
International Symposium on Clinical & Basic Investigation in Glioblastoma  
Valencia, Spain | June 2011
- *"Tumor-initiating cells in glioblastoma. Targeting the root of cancer"*  
Brain Tumor Meeting 2011  
MDC - Molecular Medicine Berlin-Buch  
Berlin, Germany | June 2011
- *"Targeting signaling pathways that mediate cancer stem cell survival"*  
ASCO Annual meeting 2011  
Chicago, USA | June 2011

- *“Células iniciadoras de tumor en glioma”*  
I Jornadas de actualización en Mecanismos Moleculares del Cáncer  
Red Temática de Investigación Cooperativa en Cáncer (RTICC)  
Santander, Spain | May 2011
- *“Células iniciadoras de cáncer como dianas terapéuticas en gliomas”*  
Simposio Internacional de Oncología Traslacional - WTC  
Barcelona, Spain | May 2011
- *“Células madre tumorales como diana terapéutica”*  
Simposio de Investigación y Terapia con células madre: avances y realidades  
Academia Médico-Quirúrgica de Santiago de Compostela  
Santiago de Compostela, Spain | March 2011
- *“Apoptosis, tumor involution and potenciales for stem cells”*  
Education Committee of the European Society of Neurology - ECNR  
European Board of Neuroradiology (EBNR)  
Roma, Italy | March 2011
- *“TGF- $\beta$  y gliomas”*  
Centro Nacional de Investigaciones Oncológicas (CNIO)  
Madrid, Spain | March 2011
- *“TGF- $\beta$  and cancer initiating cells. Targeting the root of cancer”*  
Parc de Recerca Biomèdica de Barcelona (PRBB)  
Barcelona, Spain | February 2011

## 2010

- *“Effect of TGF- $\beta$  on cancer initiating cells”*  
Oncobio 2010. Cancer, stem cells and metastasis  
Salamanca, Spain | November 2010
- *“Espacio de la radioterapia en el nuevo desarrollo de los fármacos para el tratamiento de tumores cerebrales”*  
Grupo de Investigación Clínica en Oncología Radioterápica (GICOR)  
Madrid, Spain | November 2010
- *“TGF- $\beta$  y gliomas”*  
Centro Nacional de Investigaciones Oncológicas (CNIO)  
Madrid, November | Spain 2010
- *“FoxG1 is a functional repressor of FoxO in glioblastoma and affects the anti-tumoral activity of PI3K inhibitors”*  
IRB Metabolism  
Barcelona, Spain | November 2010
- *“The TGF- $\beta$  pathway in glioma and tumor-initiating cells”*  
Danish Cancer Society  
Copenhagen, Denmark | October 2010
- *“The effect of TGF- $\beta$  on glioma and glioma-initiating cells”*  
Centro de Investigación Príncipe Felipe  
Valencia, Spain | September 2010
- *“The role of TGF- $\beta$  in glioma genesis and progression”*



7<sup>th</sup> FENS Forum of European Neuroscience  
RAI Convention Centre  
Amsterdam, The Netherlands | July 2010

- *"The effect of TGF- $\beta$  on glioma initiating cells"*  
EACR 21 - European Association for Cancer Research  
Norway Exhibition & Convention Centre  
Oslo, Norway | June 2010
- Seminarios Científicos  
Centro de Investigación del Cáncer (CIC-IBMCC)  
Salamanca, Spain | February 2010

## 2009

- *"Efecto del TGF- $\beta$  en células madre del cáncer"*  
Facultad de Ciencias y Tecnología  
Bilbao, Spain
- *"La Vía del TGF- $\beta$  como Diana terapéutica en glioma"*  
Centro Nacional de Microbiología  
Instituto de Salud Carlos III  
Madrid, Spain
- *"Papel del TGF- $\beta$  en el tumor cerebral"*  
Unidad de Cristalografía de Macromoléculas  
Instituto de Biomedicina de Valencia (CSIC)  
Valencia, Spain
- *"TGF- $\beta$  and cancer"*  
Center for Genomic Regulation (CRG)  
Barcelona, Spain
- *"Mecanismos de regulación de las células madre de glioma"*  
Universidad de Santiago de Compostela  
Santiago de Compostela, Spain
- *"TGF- $\beta$  and cancer"*  
XII Congreso Nacional ASEICA  
Madrid, Spain

## 2008

- *"Glioma initiating cells"*  
Karolinska Stem Cell Meeting  
Stockholm, Sweden
- *"TGF- $\beta$  in brain tumors"*  
European Association for Neuro-Oncology (EANO)  
Barcelona, Spain
- *"The role of TGF- $\beta$  in glioma"*  
EACR 20 - European Association for Cancer Research  
Lyon, France
- *"The oncogenic role of TGF- $\beta$  in glioma"*  
Keystone Symposia on Molecular and Cellular Biology

Santa Fe, NM, USA

## 2007

- *"The role of TGF- $\beta$  in oncogenesis"*  
Center for Genomic Regulation (CRG)  
Barcelona, Spain
- *"The dark side of TGF- $\beta$  in glioma"*  
Asociación española de Investigación sobre el cáncer. ASEICA 2007  
Las Palmas de Gran Canaria, Spain
- *"Oncogenic role of the TGF- $\beta$  pathway in glioma"*  
Nederland Cancer Institute seminars  
Amsterdam, The Netherlands
- *"The role of TGF- $\beta$  in oncogenesis"*  
TGF- $\beta$  Meeting, Ludwig Institute  
Uppsala, Sweden
- *"The role of TGF- $\beta$  in oncogenesis"*  
Brain Cancer Initiative Meeting, Ludwig Institute.  
New York, USA
- *"TGF- $\beta$  in oncogenesis"*  
Institut d'Investigació Biomèdica de Bellvitge (IDIBELL)  
Barcelona, Spain
- *"The role of TGF- $\beta$  in oncogenesis"*  
European Association for Cancer Research Symposium  
British Association for Cancer Research  
Nottingham, UK

## 2006

- *"Oncogenic role of the TGF- $\beta$  pathway in glioma"*  
I Meeting on Cell Proliferation and Cancer  
Mallorca, Spain
- *"The TGF- $\beta$  oncogenic response in glioma"*  
31<sup>st</sup> European Symposium on Hormones and Cell Regulation  
Mont-Sainte-Odile, France

## 2005

- *"Las dos caras del TGF- $\beta$  en oncogénesis"*  
Sociedad Española de Biología Celular XI Annual Symposium  
Cádiz, Spain
- *"The role TGF- $\beta$  in oncogenesis"*  
Centro Nacional de Investigaciones Oncológicas (CNIO)  
Madrid, Spain
- *"TGF- $\beta$  inhibitors"*  
Federation of European Cancer Societies  
European Cancer Conference - ECCO 13

Paris, France

- *"TGF- $\beta$  and Cancer"*  
International Symposium SFB 518  
Ulm, Germany
- *"Papel del TGF- $\beta$  en oncogénesis. Aproximación mediante análisis de microarrays de DNA"*  
Sociedad Española de Bioquímica y Biología Molecular (SEBBM) XXVIII Annual Symposium  
Zaragoza, Spain

## 2004

- *"Role of TGF- $\beta$  in oncogenesis"*  
3<sup>rd</sup> Annual Symposium on Anti-Signaling Strategies in Human Neoplasia  
Barcelona, Spain
- *"Papel del TGF- $\beta$  en glioma"*  
Tumores del sistema nervioso central: Investigación y Clínica  
Centro Nacional de Investigaciones Oncológicas (CNIO)  
Madrid, Spain
- *"Paper del TGF- $\beta$  en oncogenesis"*  
Seminari Universitat de Barcelona, Departament de Bioquímica, Campus Bellvitge  
Barcelona, Spain
- *"Papel del TGF- $\beta$  en progresión tumoral. Las dos caras del TGF- $\beta$  "*  
Seminario Instituto de Investigación Biomédica  
Madrid, Spain
- *"Curso animales modificados genéticamente: presente y futuro en la investigación biomédica"*  
Curso de Verano, Universidad de Santiago de Compostela  
Santiago de Compostela, Spain
- *"Integración de las vías del TGF- $\beta$  y PI3K-AKT en cancer. Papel de FoxG1"*  
Sociedad Española de Bioquímica y Biología Molecular (SEBBM) XXVII Annual Symposium  
Lleida, Spain
- *"Dissecting signal transduction pathways in tumorogenesis using microarray analysis"*  
Workshop on Biomedical Genomics and Proteomics  
Red Temática de Genómica y Proteómica (Generalitat- DURSI) y Red de Centros de Oncología (Nodo Vall d'Hebron)  
Conference Room, Vall d'Hebron University Hospital  
Barcelona, Spain | 10 May 2004
- *"Mecanismos de la inhibición de la proliferación celular por TGF- $\beta$ . Relevancia en Oncogénesis"*  
Seminar, Centro de Investigación del Cáncer – Instituto de Biología Molecular y Celular del Cáncer (CIC-IBMCC)  
Salamanca, Spain
- *"Mechanisms of TGF- $\beta$ -mediated inhibition of cell proliferation. Relevance in oncogenesis"*  
Seminar, Centre for Genomic Regulation (CRG)  
Barcelona, Spain
- *"Integration of Smad, FoxO and FoxG1 pathways in the TGF- $\beta$  cytostatic program"*  
EMBL/Salk/EMBO Conference on Oncogenes and Growth Control  
Heidelberg, Germany

- *“The TGF- $\beta$  cytosstatic program. Integration of Smad, Myc, PI3K and Forkhead pathways”*  
Keystone Symposia on Molecular and Cellular Biology  
Cell Cycle and Development  
Snowbird, Utah, USA